GLP-1 receptor agonists

By designing a new structure of GLP-1 receptor agonist, the side effects of existing diabetes drugs and inconvenience in insulin injection have been solved, effective blood sugar control and weight loss have been achieved without the risk of hypoglycemia.

CN114761395BActive Publication Date: 2024-11-15HYUNDAI PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080084248.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-02
Filing Date
2020-12-01
Publication Date
2024-11-15
Estimated Expiration
2040-12-01

AI Technical Summary

Technical Problem

Existing diabetes drugs have side effects while maintaining blood sugar levels, such as hypoglycemia, diarrhea, cardiovascular problems and hepatotoxicity, and insulin injection methods are inconvenient and high risk, and there is a lack of effective oral treatment options.

Method used

A new structure of GLP-1 receptor agonist has been developed. Through the specific compound structure design, it has excellent insulin secretion stimulation, glucagon inhibition, gastric emptying delay and weight loss effects, and has no risk of hypoglycemia. Maintain blood sugar stability for a long time.

Benefits of technology

The new structure of GLP-1 receptor agonist can effectively stimulate insulin secretion, inhibit glucagon, delay gastric emptying, reduce weight, and have no risk of hypoglycemia during long-term use, providing continuous blood sugar control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003677353740000021
    Figure BDA0003677353740000021
  • Figure BDA0003677353740000022
    Figure BDA0003677353740000022
  • Figure BDA0003677353740000031
    Figure BDA0003677353740000031
Patent Text Reader

Abstract

The present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein A, B, L, X and R1 to R6 are as described herein, and the compound or a pharmaceutically acceptable salt thereof acts as a GLP-1 receptor agonist and can be used to prevent or treat diseases associated with GLP-1 activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a GLP-1 receptor agonist having a novel structure. Background Art

[0002] Diabetes is a metabolic disease caused by insufficient insulin secretion or insufficient insulin action, and can be mainly divided into type 1 and type 2 according to its pathogenesis. Type 1 diabetes is caused by insufficient insulin secretion due to autoimmune destruction of pancreatic β cells. Type 2 diabetes, also known as insulin-dependent diabetes, is mainly caused by elevated blood sugar and insufficient amount of insulin produced to allow cells to absorb glucose and lower blood sugar levels. The treatment of type 1 diabetes requires insulin therapy involving external injection of insulin, while type 2 diabetes requires the administration of therapeutic agents alone or in combination, or the use of insulin therapy, depending on the progression of the disease.

[0003] Currently known oral diabetes drugs include insulin secretagogues, biguanides, α-glucosidase inhibitors, thiazolidinediones, sodium-glucose cotransporter 2 (SGLT-2) selective inhibitors, etc. Insulin secretagogues are, for example, sulfonylureas (e.g., glipizide, glimepyride, glyburide), meglitinides (e.g., nateglinide, repaglinide) and dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin, saxagliptin), etc. It is believed that the main effect of biguanides is to reduce the production of glucose in the liver, and examples thereof include metformin, etc. α-Glucosidase inhibitors reduce the absorption of glucose in the intestine, and examples thereof include acarbose, etc. Thiazolidinediones act on specific receptors (peroxisome proliferator-activated receptor γ) in the liver, muscle and adipose tissue, and examples thereof include pioglitazone, rosiglitazone, etc. SGLT-2 inhibitors inhibit glucose reuptake in the kidneys, thereby lowering blood sugar levels, and examples thereof include dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, etc.

[0004] However, in addition to the positive aspect of maintaining sustained normal blood sugar levels, oral diabetes drugs currently used in clinical practice can cause various side effects, such as hypoglycemia, diarrhea, weight gain, cardiovascular problems, hepatotoxicity in long-term use, or many of them have limited effects. In addition, the administration of insulin as a last resort treatment is inconvenient due to the need for subcutaneous injections two or three times a day, and is likely to cause the most serious side effect - hypoglycemia.

[0005] To overcome these problems, glucagon-like peptide-1 (GLP-1) receptor agonists have recently emerged as the next generation of diabetes drugs.

[0006] GLP-1 is a 30-amino acid, long-acting incretin hormone that is secreted by intestinal L cells in response to food intake. In healthy individuals, GLP-1 plays an important role in controlling postprandial blood glucose by promoting glucose-dependent insulin secretion from the pancreas. GLP-1 also inhibits glucagon secretion, resulting in reduced hepatic glucose production. In addition, GLP-1 delays gastric emptying and slows small intestinal motility, thereby delaying food absorption.

[0007] GLP-1 receptor agonists, such as GLP-1 and its analogs or derivatives, have shown good potential in the treatment of type 2 diabetes in clinical trials and induce a variety of biological effects, such as stimulating insulin secretion, inhibiting glucagon secretion, inhibiting gastric fasting, inhibiting gastric motility or intestinal motility, and causing weight loss ((i) Cardiovascular Diabetology 2014, 13: 142; (ii) Front. Neurosci. 9: 92; (iii) Peptides 100 (2018) 190-201; (iv) World J Hepatol. 2018 Nov 27; 10(11): 790-794). In addition, even if taken for a long time, GLP-1 receptor agonists can provide pancreatic protection without the risk of hypoglycemia and maintain adequate blood glucose levels for a long time. To date, known GLP-1 receptor agonists include liraglutide, albiglutide, exenatide, lixisenatide, dulaglutide, semaglutide, and the like.

[0008] Therefore, the present inventors have found through intensive studies on GLP-1 receptor agonists having a novel structure that the compounds described herein have excellent effects as GLP-1 receptor agonists, thereby completing the present invention. Summary of the invention

[0009] Technical issues

[0010] The present invention provides a GLP-1 receptor agonist with a new structure.

[0011] Solution to the problem

[0012] To solve the above problems, the present invention provides a compound represented by the following formula 1 or a pharmaceutically acceptable salt thereof:

[0013] [Formula 1]

[0014]

[0015] in,

[0016] A is for C 6-10 Aryl; C 3-7 cycloalkyl; a 5-membered or 6-membered heteroaryl containing one heteroatom selected from N, O and S; a 5-membered or 6-membered heterocycloalkyl containing one heteroatom selected from N, O and S; or a 9-membered or 10-membered fused heteroaryl containing at least one heteroatom selected from N, O and S,

[0017] B is any one of the following (1) to (5),

[0018]

[0019] L is -(CH2) n -O-, -O-(CH2) n -、-(CH2) n -NH-, -NH-(CH2) n -、-(CH2) n -N(C 1-5 Alkyl)-, -N(C 1-5 Alkyl)-(CH2) n -, -CONH- or -NHCO-, wherein n is 1 or 2,

[0020] X is CH or N,

[0021] R1 and R2 are each independently selected from hydrogen, C 1-5 Alkyl, C 1-5 Alkoxy, C 1-5 The group consisting of haloalkyl, halogen, cyano and nitro,

[0022] R3 is hydrogen or halogen,

[0023] R4 and R5 are each independently selected from hydrogen, C 1-5 Alkyl, C 1-5 Alkoxy, C 1-5 The group consisting of haloalkyl, halogen, cyano and nitro,

[0024] R6 is -(CH2) m -O-(C 1-5 alkyl) (wherein m is 1 or 2); C 1-5 Haloalkyl; unsubstituted or C 1-5 Alkyl-substituted 5-membered or 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S; or unsubstituted or C 1-5 The alkyl-substituted 4-membered or 5-membered heterocycloalkyl group contains one heteroatom selected from N, O and S.

[0025] In Formula 1, the symbols "*1" and "*2" shown in B represent respective bonding positions. That is, in Formula 1, each compound has the following structures (1) to (5) of B.

[0026]

[0027] Preferably, A is phenyl; C 3-7 cycloalkyl; a 5-membered or 6-membered heteroaryl containing one heteroatom selected from N, O and S; or a 9-membered or 10-membered benzo-fused ring fused to a 5-membered or 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S. More preferably, A is phenyl, pyrrolyl, pyridyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, cyclopropyl or cyclobutyl. More preferably, A is phenyl, pyridyl, benzothiazolyl or cyclopropyl.

[0028] Preferably L is -(CH2) n -O- or -O-(CH2) n -(n is 1 or 2), more preferably L is -CH2O- or -OCH2-.

[0029] Preferably, R1 is hydrogen, C 1-5 Alkyl, C 1-5 Alkoxy, C 1-5 Haloalkyl, halogen, cyano or nitro, R2 is hydrogen or halogen.

[0030] More preferably, R1 is hydrogen, methyl, methoxy, trifluoromethyl, fluorine, chlorine, bromine, cyano or nitro, and more preferably, R2 is hydrogen, fluorine, chlorine or bromine.

[0031] Preferably, R3 is hydrogen, fluorine, chlorine or bromine.

[0032] Preferably, R4 is hydrogen, C 1-5 Alkyl, C 1-5 alkoxy, halogen or nitro, and R5 is hydrogen or halogen.

[0033] More preferably, R4 is hydrogen, methyl, methoxy, fluorine, chlorine, bromine or nitro, and more preferably, R5 is hydrogen, fluorine, chlorine or bromine.

[0034] Preferably, R6 is -(CH2) m -O-(C 1-5 alkyl)(m is 1); C 1-5 haloalkyl; heteroaryl selected from thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl and pyrazinyl, wherein the heteroaryl is unsubstituted or replaced by C 1-5 or a heterocycloalkyl group selected from oxetanyl, azetidinyl, tetrahydrofuranyl and pyrrolidinyl.

[0035] More preferably, R6 is -CH2-O-CH3; -CH2F; furyl; imidazolyl which is unsubstituted or substituted with methyl or ethyl; oxazolyl; pyridyl; thienyl; oxetanyl; or tetrahydrofuranyl.

[0036] Preferably, Formula 1 is represented by the following Formula 1-1:

[0037] [Formula 1-1]

[0038]

[0039] in

[0040] Y is CH or N,

[0041] A, L, X and R1 to R6 are as defined above.

[0042] Preferably, Formula 1 is represented by the following Formula 1-2:

[0043] [Formula 1-2]

[0044]

[0045] in

[0046] Y is CH or N,

[0047] X and R1 to R6 are as defined above.

[0048] Preferably, Formula 1 is represented by the following Formula 1-3:

[0049] [Formula 1-3]

[0050]

[0051] in

[0052] Z is CH or N,

[0053] A, L, X and R1, R2, R3 and R6 are as defined above.

[0054] Preferably, Formula 1 is represented by the following Formula 1-4:

[0055] [Formula 1-4]

[0056]

[0057] in

[0058] Z is CH or N,

[0059] X and R1, R2, R3 and R6 are as defined above.

[0060] Representative examples of the compounds represented by Formula 1 are as follows:

[0061] 1) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0062] 2) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0063] 3) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0064] 4) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0065] 5) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0066] 6) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0067] 7) 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0068] 8) 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0069] 9) 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0070] 10) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0071] 11) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0072] 12) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0073] 13) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0074] 14) 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0075] 15) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0076] 16) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0077] 17) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0078] 18) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0079] 19) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0080] 20) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0081] 21) 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0082] 22) 2-((3′-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0083] 23) 1-(furan-2-ylmethyl)-2-((5-(3-(3-methoxybenzyloxy)phenyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0084] 24) 2-((3′-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0085] 25) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0086] 26) 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0087] 27) 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0088] 28) 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0089] 29) 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-methylbiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0090] 30) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0091] 31) 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0092] 32) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0093] 33) 2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0094] 34) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0095] 35) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0096] 36) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0097] 37) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0098] 38) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0099] 39) 2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0100] 40) 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0101] 41) (R)-2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0102] 42) (R)-2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0103] 43) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0104] 44) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0105] 45) (R)-2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0106] 46) (R)-2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0107] 47) (R)-2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0108] 48) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3,5-difluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0109] 49) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(thien-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0110] 50) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0111] 51) (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0112] 52) (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0113] 53) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0114] 54) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0115] 55) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0116] 56) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0117] 57) 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0118] 58) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0119] 59) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0120] 60)(S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0121] 61) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0122] 62) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0123] 63) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0124] 64) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0125] 65) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0126] 66) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0127] 67) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0128] 68) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0129] 69) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0130] 70) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0131] 71) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0132] 72) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0133] 73) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0134] 74) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0135] 75) 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0136] 76) 2-(2-fluoro-4-(6-(4-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0137] 77) 2-(2-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0138] 78) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0139] 79) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0140] 80) 2-(2-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0141] 81) 2-(2-fluoro-4-(6-(3-methoxybenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0142] 82) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0143] 83) 2-(4-(6-(Benzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0144] 84) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0145] 85) 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0146] 86) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0147] 87) 2-(4-(6-(4-cyanobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0148] 88) 2-(2-fluoro-4-(6-(4-nitrobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0149] 89) 2-(4-(6-(4-bromo-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0150] 90) 2-(3-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0151] 91) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)-5-fluoropyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0152] 92) 2-((3′-(4-chloro-2-fluorobenzyloxy)-2,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0153] 93) 2-((3′-(4-cyano-2-fluorobenzyloxy)-2,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0154] 94) 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0155] 95) 2-((3′-(4-chloro-2-fluorobenzyloxy)-3,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0156] 96) 2-((3′-(4-cyano-2-fluorobenzyloxy)-3,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0157] 97) 2-(3-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0158] 98) 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0159] 99) 2-(4-(6-(4-chloro-3-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0160] 100) 2-(4-(6-(3-chloro-5-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0161] 101) 2-(4-(6-(2-chloro-6-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0162] 102) 2-((5-(3-(4-chloro-2-fluorobenzyloxy)-4-fluorophenyl)pyridin-2-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0163] 103) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0164] 104) 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0165] 105) 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0166] 106) 2-((4-(3-(4-chloro-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0167] 107) 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0168] 108) (S)-2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0169] 109) (S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0170] 110) (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0171] 111)(S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0172] 112) 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-6-oxopyrimidin-1(6H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0173] 113) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0174] 114) 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0175] 115) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0176] 116) (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0177] 117) (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0178] 118) (S)-2-(4-(6-((4-cyanobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0179] 119) (S)-2-(4-(6-((2,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0180] 120) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0181] 121)(S)-2-(3-fluoro-4-(6-((4-(trifluoromethyl)benzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0182] 122) (S)-2-(3-fluoro-4-(6-((4-methoxybenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0183] 123) (S)-2-(4-(6-((4-chlorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0184] 124) (S)-2-(3-fluoro-4-(6-((4-nitrobenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0185] 125) (S)-2-(4-(6-((3,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0186] 126) (S)-2-(4-(6-((2-chloro-6-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0187] 127) 2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0188] 128) (S)-2-(3-fluoro-4-(6-(pyridin-4-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0189] 129) (S)-2-(3-fluoro-4-(6-(pyridin-3-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0190] 130) 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0191] 131)(S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0192] 132) (S)-2-(4-(6-(Benzo[d]thiazol-2-ylmethoxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0193] 133) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid,

[0194] 134) (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, and

[0195] 135)(S)-2-(4-(6-(Cyclopropylmethoxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid.

[0196] As used herein, “C 1-5 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 5 carbon atoms. For example, C 1-5 Alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 1-methylbutyl, and 1,1-dimethylpropyl.

[0197] The term "C1-5 "Alkoxy" is an OR group, wherein R is C as defined above 1-5 Examples of the alkoxy group having 1 to 5 carbon atoms include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, 1-methylethoxy, 1,1-dimethylethoxy, 1-methylpropoxy, 2-methylpropoxy, or cyclopropylmethoxy.

[0198] The term "C 1-5 "Haloalkyl" is a C 1-5 Alkyl groups wherein one or more hydrogen atoms are substituted by one or more halogen atoms. Examples include, but are not limited to, difluoromethyl or trifluoromethyl groups.

[0199] As used herein, "halo" is fluoro, chloro or bromo.

[0200] The term "C 3-7 "Cycloalkyl" refers to a saturated hydrocarbon ring system having 3 to 7 ring carbon atoms. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

[0201] The term "aryl" refers to a C 6-10 Aryl, preferably C6 aryl (ie phenyl).

[0202] The term "heteroaryl" refers to an aromatic ring system containing one or more heteroatoms selected from N, O and S, preferably a 5-membered or 6-membered monocyclic aromatic ring system. Examples of 5-membered or 6-membered heteroaryl groups include, but are not limited to, pyrrolyl, thienyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, imidazolyl, isoxazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, and the like.

[0203] The term "fused heteroaryl" refers to a ring system in which a heteroaryl is connected to other aryl, heteroaryl or heterocycloalkyl in a fused manner, preferably a 9-membered or 10-membered benzo-fused heteroaryl. Examples of fused heteroaryl include, but are not limited to, benzofuranyl, isobenzofuranyl, benzothiophenyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, benzotriazolyl, quinolyl, isoquinolyl, quinazolinyl, and the like.

[0204] The term "heterocycloalkyl" refers to a saturated or partially unsaturated ring system containing one or more heteroatoms selected from N, O and S, preferably a 4-, 5- or 6-membered heterocycloalkyl. Examples of heterocycloalkyl include, but are not limited to, oxirane, aziridine, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, 3-pyrrolinyl, 2-pyrrolinyl, 2H-pyrrolyl, 1H-pyrrolyl, imidazolidinyl, 2-imidazolinyl, pyrazolidinyl, 2-pyrazolinyl, oxazolidinyl, isoxazolidinyl, isothiazolidinyl, thiazolidinyl, oxadiazolidinyl, thiadiazolidinyl, tetrahydropyranyl, 2H-pyranyl, 4 H-pyranyl, piperidinyl, morpholinyl, thianyl, 2H-thiopyranyl, 4H-thiopyranyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, dioxolanyl, oxathiolanyl, 1,4-dioxanyl, oxazinyl, thiazinyl, and the like.

[0205] In addition, the compound of the present invention can exist in the form of a salt, particularly a pharmaceutically acceptable salt. Preferably, a pharmaceutically acceptable salt is a metal salt, more preferably a sodium salt, a potassium salt, a cesium salt, a lithium salt, a magnesium salt or a calcium salt. Metal salts can be prepared using an inorganic base or an organic base. For example, the compound represented by Formula 1 is dissolved in an organic solvent (such as acetone, methanol, ethanol or acetonitrile) that is miscible with water, and then an organic base or an inorganic base is added thereto, and then a precipitated crystal is prepared by filtering, and dried to obtain a pharmaceutically acceptable salt. Alternatively, a pharmaceutically acceptable salt can be prepared by vacuuming the solvent from a reaction mixture to which a base is added, then drying the residue, or by adding another organic solvent and filtering the precipitated salt. In addition, the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (such as silver nitrate).

[0206] In addition, salt can be prepared using various organic bases and metal salts, and typically, tri-salt can be prepared using tris(hydroxymethyl)aminomethane. In addition, pharmaceutically acceptable salts can be prepared using basic amino acids. As amino acid salts, it is pharmaceutically suitable to prepare natural amino acid salts such as arginine, histamine, and lysine.

[0207] Meanwhile, a pharmaceutically unacceptable salt or solvate of the compound represented by Formula 1 may be used as an intermediate for preparing the compound represented by Formula 1 or a pharmaceutically acceptable salt or solvate thereof.

[0208] The compound represented by Formula 1 of the present invention includes not only its pharmaceutically acceptable salt, but also all possible solvates and hydrates that can be prepared therefrom, and also all possible stereoisomers. The solvates, hydrates and stereoisomers of the compound represented by Formula 1 can be prepared and used by the compound represented by Formula 1 using conventional methods.

[0209] In addition, the compound represented by Formula 1 according to the present invention can be prepared in a crystalline form or an amorphous form. When prepared in a crystalline form, the compound represented by Formula 1 can be optionally hydrated or solvated. The present invention may include stoichiometric hydrates of the compound represented by Formula 1 and compounds containing various amounts of water. The solvates of the compound represented by Formula 1 according to the present invention include stoichiometric solvates and non-stoichiometric solvates.

[0210] In addition, as an embodiment, the compound represented by Formula 1 can be prepared using the preparation method shown in the following Reaction Scheme 1.

[0211] [Reaction Scheme 1]

[0212]

[0213] In Reaction Scheme 1, the definitions except for X' are as defined above, X' is halogen, preferably chlorine or bromine.

[0214] Step 1-1 is a Suzuki coupling reaction, in which a compound represented by formula C is prepared by reacting a compound represented by formula A with a compound represented by formula B. The reaction is preferably carried out in the presence of a palladium catalyst and a base, and the reactor used for the Suzuki coupling reaction can be modified according to common knowledge in the art.

[0215] Step 1-2 is a hydrolysis reaction, in which the methyl ester group (or ethyl ester group) is converted into a carboxyl group. The reaction is preferably carried out in the presence of a base, and the reaction conditions of the hydrolysis reaction can be applied according to common knowledge in the art.

[0216] The preparation method of Reaction Scheme 1 can be described in more detail in the Examples described below.

[0217] In addition, as an embodiment, the compound represented by Formula 1 can be prepared using the preparation method shown in the following Reaction Scheme 2.

[0218] [Reaction Scheme 2]

[0219]

[0220] In Reaction Scheme 2, the definitions except for X' are as defined above, X' is halogen, preferably chlorine or bromine.

[0221] Step 2-1 is a Suzuki coupling reaction, in which a compound represented by formula E is prepared by reacting a compound represented by formula A with a compound represented by formula D. The reaction is preferably carried out in the presence of a palladium catalyst and a base, and the reactor used for the Suzuki coupling reaction can be modified according to common knowledge in the art.

[0222] Step 2-2 is a hydrolysis reaction, in which the methyl ester group (or ethyl ester group) is converted into a carboxyl group. The reaction is preferably carried out in the presence of a base, and the reaction conditions of the hydrolysis reaction can be applied according to common knowledge in the art.

[0223] Step 2-3 is an amidation reaction, in which the compound represented by formula F reacts with the compound represented by formula D to prepare the compound represented by formula H. The reaction conditions of the amidation reaction can be applied according to common knowledge in the art.

[0224] Step 2-4 is a cyclization reaction, wherein the compound represented by formula H reacts under acidic conditions to form a benzimidazole ring. The reaction conditions of the cyclization reaction can be applied according to common knowledge in the art.

[0225] Step 2-5 is a hydrolysis reaction, wherein the methyl ester group (or ethyl ester group) is converted into a carboxyl group. The reaction is preferably carried out in the presence of a base, and the reaction conditions of the hydrolysis reaction can be applied according to common knowledge in the art.

[0226] The preparation method of Reaction Scheme 2 can be described in more detail in the Examples described below.

[0227] In addition, the present invention provides a pharmaceutical composition for preventing or treating a disease associated with GLP-1 activity, the pharmaceutical composition comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof as an active ingredient.

[0228] That is, the compound represented by Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof as a GLP-1 receptor agonist induces effects such as stimulation of insulin secretion, inhibition of glucagon secretion, inhibition of fasting gastric juice, inhibition of gastric motility or intestinal motility, and causing weight loss, and thus can be usefully used for preventing or treating diseases associated with GLP-1 activity.

[0229] Examples of diseases associated with GLP-1 activity include diabetes, hyperglycemia, insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, obesity, glucose metabolism disorders, hyperlipidemia, dyslipidemia, cardiovascular disease, arteriosclerosis, nonalcoholic fatty liver disease, or nonalcoholic steatohepatitis.

[0230] As used herein, the term "prevention" refers to any action that inhibits or delays the development, spread and recurrence of a disease by administering the pharmaceutical composition of the present invention, and as used herein, the term "treatment" refers to any action that alleviates or favorably changes the symptoms of a disease by administering the pharmaceutical composition of the present invention.

[0231] The pharmaceutical composition of the present invention can be formulated into oral dosage forms or parenteral dosage forms according to standard pharmaceutical practice. In addition to the active ingredients, these preparations may contain additives such as pharmaceutically acceptable carriers, adjuvants or diluents.

[0232] Carriers suitably include but are not limited to for example physiological saline, polyethylene glycol, ethanol, vegetable oil and isopropyl myristate etc., and diluents suitably include but are not limited to lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine etc. In addition, the compound of the present invention can be dissolved in oil, propylene glycol or other solvents that are usually used to prepare injections. In addition, the compound of the present invention can be formulated into an ointment or cream for local action.

[0233] The pharmaceutical dosage forms of the compounds of the present invention may be used in the form of pharmaceutically acceptable salts or solvates thereof, and may be used alone or in combination with other pharmaceutically active compounds, or may be used in an appropriate kit.

[0234] The compound of the present invention can be dissolved, suspended or emulsified in ordinary saline, water-soluble solvents (such as 5% glucose) or water-insoluble solvents (such as synthetic fatty acid glycerides, higher fatty acid esters or propylene glycol) to be prepared as injections. The preparation of the present invention may include conventional additives, such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives.

[0235] The preferred dosage of the compounds of this invention depends on the patient's condition and body weight, the degree of the disease, the form of the therapeutic agent, the route of administration and the duration, but can be suitably selected by those skilled in the art. However, in order to obtain the desired effect, the compounds of this invention can be used with 0.0001mg / kg (body weight) to 100mg / kg (body weight) every day, preferably 0.001mg / kg (body weight) to 100mg / kg (body weight). The compound can be used once a day or in divided doses by oral route or parenteral route. According to the method of application, the composition can contain 0.001wt.% to 99wt.%, preferably 0.01wt.% to 60wt.% of the compounds of this invention.

[0236] The pharmaceutical composition of the present invention can be administered to mammals, including rats, mice, livestock and humans, by various routes. All administration methods are contemplated, and the composition can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or intracerebroventricular injection.

[0237] Advantageous Effects of the Invention

[0238] The compound according to the present invention or a pharmaceutically acceptable salt thereof can be used as a GLP-1 receptor agonist to prevent or treat diseases associated with GLP-1 activity. DETAILED DESCRIPTION

[0239] Hereinafter, in order to illustrate the present invention in detail, the following examples are given. However, the following examples are provided only to illustrate the present invention, and the scope of the present invention is not limited by the following examples.

[0240] Example 7: Preparation of 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0241] Step 1) Preparation of 2-chloro-6-((4-chloro-2-fluorophenoxy)methyl)pyridine

[0242]

[0243] 4-Chloro-2-fluorophenol (5.7 g, 26.00 mmol) and dimethylformamide (60 mL) were added to a 250 mL two-necked flask, stirred for 5 minutes to dissolve, then (6-chloropyridin-2-yl) methyl methanesulfonate (3.47 g, 23.60 mmol) and cesium carbonate (15.42 g, 47.30 mmol) were added, and then stirred at room temperature for 2 hours. After the reaction was completed, distilled water (100 mL) was added to the flask containing the resulting mixture to form a solid compound. The resulting product was filtered under reduced pressure and dried to obtain the target compound (6.27 g, 23.00 mmol, yield: 97.3%).

[0244] 1 H NMR (400MHz, CDCl3) δ7.72-7.68 (t, 1H), 7.50-7.48 (d, 1H), 7.29-7.27 (d, 1 H), 7.15-7.12(dd, 1H), 7.05-7.01(dt, 1H), 6.92-6.88(t, 1H), 5.20(s, 2H)

[0245] Step 2) Preparation of methyl 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl-1H-benzo[d]imidazole-6-carboxylate

[0246]

[0247] 2-Chloro-6-((4-chloro-2-fluorophenoxy)methyl)pyridine (3.53 g, 13.00 mmol) prepared in step 1 and tetrahydrofuran:ethanol:distilled water (4:2:1 (volume ratio); 20 mL, 10 mL, 5 mL; 35 mL in total) were added to a 250 mL three-necked flask and stirred for 5 minutes to dissolve. Then, 1-(2-methoxyethyl)-2-(2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (5.69 g, 11.82 mmol), tripotassium phosphate (7.52 g, 35.4 mmol) and Pd(dppf)Cl2.CH2Cl2 (0.96 g, 1.18 mmol) were added, slowly heated to 80°C, and then stirred for 2 hours using a reflux cooler. After the reaction was completed, the resulting mixture was cooled to room temperature for 30 minutes. Then, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate (40 mL) and distilled water (20 mL), and the organic layer was separated. After separation, the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent. Thereafter, column chromatography was used for separation under the conditions of ethyl acetate: n-hexane (1:5 (volume ratio)). The obtained compound was concentrated under reduced pressure to obtain the target compound (0.158 g, 0.26 mmol, yield 22.09%).

[0248] 1 H NMR (400MHz, CDCl3) δ8.87 (s, 1H), 8.44-8.39 (dd, 2H), 8.10 (s, 1H), 7.95-7.94 (d, 1H), 7.92-7.87 (t, 1H), 7.78-7.68 (d, 1H), 7.59-7.57 (d, 1H) ), 7.16-7.00(t, 2H), 6.78(s, 1H), 5.34(s, 2H), 4.99(s, 1H), 4.86-4.82 (m, 1H), 4.66-4.62 (d, 1H), 3.95-3.88 (d, 5H), 3.43 (s, 3H), 3.25 (s, 3H)

[0249] Step 3) Preparation of 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0250]

[0251] In a 100 mL single-necked flask, methyl 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl-1H-benzo[d]imidazole-6-carboxylate (3.4 g, 5.61 mmol) prepared in step 2 and tetrahydrofuran:methanol:distilled water (4:2:1 (volume ratio); 20 mL, 10 mL, 5 mL; 35 mL in total) were added and stirred for 10 minutes to dissolve. Then, 2N potassium hydroxide aqueous solution (20 mL) was added and stirred at room temperature for 4 hours. After the reaction was completed, the mixed solution was concentrated under reduced pressure. 2N hydrochloric acid aqueous solution (10 mL) was added and neutralized to pH 7-8 to produce a solid compound. The resultant was filtered under reduced pressure and dried, thereby obtaining the target compound (2.7 g, 4.56 mmol, yield: 81.3%).

[0252] 1 H NMR (400MHz, DMSO) δ8.91-8.90 (d, 1H), 8.69-8.65 (m, 1H), 8.40 (s, 1H), 8.25- 8.23 (d, 1H), 8.12-8.10 (t, 1H), 8.03-7.98 (d, 1H), 7.96-7.88 (d, 1H), 7.77-7. 71(t,1H),7.65-7.63(d,1H),7.51-7.48(dd,1H),7.40-7.34(t,1H),7.25-7.2 2(m, 1H), 5.44-5.38(d, 2H), 3.87-3.84(t, 2H), 3.44-3.31(s, 2H), 3.25(s, 3H)

[0253] Example 60: Preparation of (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0254] Step 1) Preparation of 2-bromo-6-((4-chloro-2-fluorobenzyl)oxy)pyridine

[0255]

[0256] 6-bromopyridine-2-ol (5 g, 28.73 mmol) was added to a 250 mL flask and dissolved by adding dimethylformamide (25 mL). After adding cesium carbonate (18.40 g, 56.46 mmol), 1-(bromomethyl)-4-chloro-2-fluorobenzene (7.70 g, 34.48 mmol) was then added and stirred at room temperature for 2 hours. When the reaction was complete, distilled water (100 mL) was added and stirred for 30 minutes, and the solid obtained was then filtered to obtain the target compound (8.6 g, yield: 94%).

[0257] 1 H NMR (400MHz, CDCl3) δ8.13-8.09 (m, 1H), 7.97-7.94 (m, 2H), 4.01 (s, 3H)

[0258] Step 2) Preparation of methyl 2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetate

[0259]

[0260] 2-Bromo-6-((4-chloro-2-fluorobenzyl)oxy)pyridine (5 g, 15.80 mmol), 2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid methyl ester (5.58 g, 18.95 mmol), Pd(dppf)Cl2.CH2Cl2 (645 mg, 0.79 mmol) and tripotassium phosphate (6.70 g, 31.6 mmol) prepared in step 1 were added to a 250 mL flask in sequence, dissolved in methanol (35 mL), tetrahydrofuran (25 mL) and distilled water (15 mL), and stirred for 2 hours using a reflux cooler. When the reaction was complete, the reaction product was concentrated under reduced pressure, then distilled water (30 mL) was added, and then extracted with ethyl acetate (50 mL). The extracted organic layer was dried over anhydrous magnesium sulfate and filtered under reduced pressure. The filtered solution was concentrated under reduced pressure and then separated by a column, thereby obtaining the target compound (4.7 g, yield: 73%).

[0261] 1 H NMR (400MHz, CDCl3) δ8.03-7.97 (t, 1H), 7.67-7.62 (t, 1H), 7.48-7.44 (m, 2H), 7.18-7.09 (m, 4H), 6.77-6.75 (d, 1H), 5.50 (s, 2H), 4.21-4.15 (m, 2H), 3.65 (s, 2H), 1.34-1.24 (m, 3H)

[0262] Step 3) Preparation of methyl 2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetic acid

[0263]

[0264] In a 100mL flask, methyl 2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetate (3g, 7.43mmol) prepared in step 2 was dissolved in methanol (15mL) and distilled water (15mL), and then 2N potassium hydroxide aqueous solution (3mL) was added and stirred at room temperature for 8 hours. When the reaction was completed, the reaction product was concentrated under reduced pressure, and then 1N hydrochloric acid aqueous solution (8mL) was added, followed by extraction with distilled water (20mL) and ethyl acetate (30mL). The extracted organic layer was dried over anhydrous magnesium sulfate and filtered under reduced pressure. The filtered solution was concentrated under reduced pressure, and the resulting solid was filtered with a normal hexane solution, thereby obtaining the target compound (2.78g, yield: 96%).

[0265] 1 H NMR (400MHz, CDCl3) δ8.00 (t, 1H), 7.66 (t, 1H), 7.48-7.44 (m, 2H), 7.19 (d, 1H), 7.14-7.10 (m, 3H), 6.75 (d, 1H), 5.49 (s, 2H), 3.71 (s, 2H)

[0266] Step 4: Preparation of (S)-methyl 4-(2-(2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetylamino)-3-(((tetrahydrofuran-2-yl)methyl)amino)benzoate

[0267]

[0268] Into a 100mL flask, (S)-4-amino-3-(((tetrahydrofuran-2-yl)methyl)amino)benzoic acid methyl ester (3g, 11.99mmol), methyl 2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetic acid (5.61g, 14.38mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.60g, 23.98mmol) and dimethylaminopyridine (2.94g, 23.98mmol) were added successively, then dissolved in dichloromethane (30mL), and stirred at room temperature for 5 hours. When the reaction was complete, 1N hydrochloric acid aqueous solution (10mL) was added, followed by extraction with distilled water (20mL) and dichloromethane (30mL). The extracted organic layer was dried over anhydrous magnesium sulfate and filtered under reduced pressure. The filtered solution was concentrated under reduced pressure, ethyl acetate (10 mL) was added, and then n-hexane (30 mL) was added, followed by stirring for 30 minutes. The obtained solid was filtered with a n-hexane solution, thereby obtaining the target compound (4.13 g, yield 55%).

[0269] 1 H NMR (400MHz, CDCl3) δ 8.12-8.08 (t, 1H), 7.80-7.78 (d, 1H), 7.69-7.67 (m, 2H), 7.65-7.44 (m, 4H), 7.28-7.26 (d, 1H), 7.18-7.13 (m, 3H), 6 .79-6.77(d,1H),5.49(s,2H),3.99-3.97(m,1H),3.87(s,3H),3.84- 3.82(m, 3H), 3.80-3.78(m, 1H), 3.08-2.97(m, 2H), 1.86-1.54(m, 4H)

[0270] Step 5: Preparation of (S)-methyl 2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0271]

[0272] To a 100 mL flask was added (S)-4-(2-(2-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorophenyl)acetamido)-3-(((tetrahydrofuran-2-yl)methyl)amino)benzoic acid methyl ester (3 g, 4.82 mmol) prepared in step 4, followed by addition of acetic anhydride (30 mL) and stirring for 2 hours using a reflux cooler. When the reaction was complete, the reaction product was extracted with distilled water (50 mL) and ethyl acetate (30 mL). The extracted organic layer was washed twice with saturated sodium bicarbonate aqueous solution (50 mL) and the organic layer was separated. The separated organic layer was dried over anhydrous magnesium sulfate and then filtered under reduced pressure. The filtered solution was concentrated under reduced pressure, ethyl acetate (10 mL) was added, and then normal hexane (30 mL) was added, followed by stirring for 30 minutes. The solid obtained was filtered with a normal hexane solution to obtain the target compound (2.71 g, 92% yield).

[0273] 1 H NMR (400MHz, CDCl3) δ8.10 (s, 1H), 8.05-7.95 (m, 2H), 7.75 (d, 1H), 7.65 (t, 1H), 7.45 (m, 2H), 7.20-7.05 (m, 4H), 6.75 (d, 1H), 5.49 (s, 2H), 4.50 (q, 2H), 4.30-4.10 (m, 3H), 3.85 (m, 1H), 3.75 (m.1H), 2.05 (m, 1H), 1.95 (m, 2H), 1.55 (m, 1H)

[0274] Step 6) Preparation of S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0275]

[0276] In a 100 mL flask, (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (1 g, 1.65 mmol) prepared in step 5 was dissolved in methanol (5 mL) and distilled water (5 mL), and then the prepared 2N potassium hydroxide aqueous solution (1 mL) was added, followed by stirring at room temperature for 8 hours. When the reaction was completed, the reaction product was concentrated under reduced pressure, and then 1N hydrochloric acid aqueous solution (3 mL) was added, followed by extraction with distilled water (10 mL) and ethyl acetate (15 mL). The extracted organic layer was dried over anhydrous magnesium sulfate and filtered under reduced pressure. The filtered solution was concentrated under reduced pressure, and the resulting solid was filtered with a n-hexane solution, thereby obtaining the target compound (742 mg, yield: 76%).

[0277] 1 H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.98-7.93 (t, 1H), 7.85-7.79 (m, 2H), 7.64- 7.57(m, 2H), 7.50-7.43(m, 2H), 7.33-7.29(m, 3H), 6.90-6.88(d, 1H), 5.47(s, 2H), 4.53-4.45(m, 3H), 4.36-4.30(m, 1H), 4.11-4.09(m, 1H), 3.78-3.75(q, 1 H), 3.61-3.33(q, 1H), 2.04-2.00(m, 1H), 1.91-1.81(m, 2H), 1.78-1.63(m, 1H)

[0278] Example 110: Preparation of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0279] Step 1) Preparation of 2-bromo-6-((4-chloro-2-fluorobenzyl)oxy)pyridine

[0280]

[0281] 6-bromopyridine-2-ol (5 g, 28.73 mmol) was added to a 250 mL flask and dissolved by adding dimethylformamide (25 mL). After adding cesium carbonate (18.40 g, 56.46 mmol), 1-(bromomethyl)-4-chloro-2-fluorobenzene (7.70 g, 34.48 mmol) was then added and stirred at room temperature for 2 hours. When the reaction was complete, distilled water (100 mL) was added and stirred for 30 minutes. Then, the solid obtained was filtered to obtain the target compound (8.6 g, yield: 94%).

[0282] 1 H NMR (400MHz, CDCl3) δ8.13-8.09 (m, 1H), 7.97-7.94 (m, 2H), 4.01 (s, 3H)

[0283] Step 2) Preparation of 6-((4-chloro-2-fluorobenzyl)oxy)-2′-((4-methoxybenzyl)oxy)-2,4′-bipyridine

[0284]

[0285] In a 100 mL flask, 2-bromo-6-((4-chloro-2-fluorobenzyl)oxy)pyridine (780 mg, 2.5 mmol) and 2-((4-methoxybenzyl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (870 mg, 2.55 mmol) previously prepared in step 1 were dissolved in tetrahydrofuran: distilled water: methanol (4:2:1 (volume ratio); 20 mL, 10 mL, 5 mL; total 35 mL). Calcium phosphate (1.08 g, 5 mmol) and tetrakis(triphenylphosphine)palladium(0) (90 mg, 0.12 mmol) were added to the reaction mixture. The final mixture was stirred at 68°C for 4 hours. After the reaction was completed, ethyl acetate and distilled water were added, and then the organic layer was extracted. The organic layer was dried over anhydrous magnesium sulfate, filtered, and distilled under reduced pressure. The obtained product was purified by column chromatography (ethyl acetate:dichloromethane:n-hexane=1:1:8 (volume ratio)), and solidified with ethyl acetate and n-hexane, thereby obtaining the target compound (890 mg, yield: 80%).

[0286] 1 H NMR (400MHz, CDCl3) δ8.28 (d, 1H), 7.70-7.65 (t, 1H), 7.49-7.40 (m, 6H), 7.15-7.11 (m, 2H), 6.94-6.91 (d, 2H), 6.83-7.81 (d, 1H), 5.51 (s, 2H), 5.36 (s, 2H), 3.81 (s, 3H)

[0287] Step 3) Preparation of 6-((4-chloro-2-fluorobenzyl)oxy)-[2,4′-bipyridine]-2′(1′H)-monohydrochloride

[0288]

[0289] In a 100 mL flask, 6-((4-chloro-2-fluorobenzyl)oxy)-2′-((4-methoxybenzyl)oxy)-2,4′-bipyridine (890 mg, 2 mmol) previously prepared in step 2 was dissolved in dichloromethane (8 mL). 2 mL of 4N aqueous hydrochloric acid solution (1,4-dioxane solvent) was added at room temperature, followed by stirring for 5 hours. After the reaction was completed, ethyl acetate (20 mL) was added and filtered to obtain the target compound (620 mg, yield 86%) in the form of a solid.

[0290] 1 H NMR (400MHz, DMSO) δ7.91-7.87 (t, 1H), 7.70-7.62 (m, 2H), 7.55-7.52 (m, 2H), 8. 37-7.35(d,1H),7.09(s,1H),7.01-6.99(d,1H),6.92-6.91(d,1H),5.53(s,2H)

[0291] Step 4: Preparation of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0292]

[0293] 6-((4-chloro-2-fluorobenzyl)oxy)-[2,4′-bipyridine]-2′(1′H)-monohydrochloride (620 mg, 1.74 mmol) previously prepared in step 3 was transferred to a 100 mL flask and dissolved in dimethylformamide (17 mL). At room temperature, triethylamine (0.24 mL, 1.74 mmol) and (S)-2-(chloromethyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (511 mg, 1.74 mmol) and cesium carbonate (849 mg, 2.60 mmol) were added in sequence. The final mixture was stirred at 60° C. for 2.5 hours. After the reaction was completed, ethyl acetate and distilled water were added and the organic layer was extracted. The organic layer was washed twice with distilled water, dried over anhydrous magnesium sulfate, filtered, and then distilled under reduced pressure. The concentrated compound was purified by column chromatography (dichloromethane:ethyl acetate=1:1 (volume ratio)) and then solidified, thereby obtaining the target compound (700 mg, yield: 70%).

[0294] 1 H NMR (400MHz, CDCl3) δ8.14 (s, 1H), 7.99-7.97 (d, 1H), 7.84-7.82 (d, 1H), 7.76-7.65 (m, 2H), 7.44-7.11 (m, 4H), 6.91-6.68 (m, 3H), 5.71-5 .68(d,1H),5.51-5.41(m,4H),5.38-5.32(m,1H),5.00-4.96(m,1H), 4.72-4.48(m, 3H), 3.94(s, 3H), 2.88-2.85(m, 1H), 2.50-2.47(m, 1H)

[0295] Step 5 Preparation of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0296]

[0297] (S)-methyl 2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (700 mg, 1.21 mmol) prepared previously in step 4 was transferred to a 100 mL flask and dissolved in tetrahydrofuran: distilled water: methanol (2:1:2 (volume ratio); 10 mL, 5 mL, 10 mL; total 25 mL). Lithium hydroxide (152 mg, 3.62 mmol) was added at room temperature, followed by stirring at room temperature for 12 hours. After completion of the reaction, the reaction product was neutralized with 1N aqueous hydrochloric acid to pH 6-7, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered and distilled under reduced pressure. The solvent was removed, and the residue was then solidified with ethyl acetate, whereby the target compound (480 mg, yield: 70%) was obtained.

[0298] 1 H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.99-7.97 (d, 1H), 7.88 (t, 1H), 7.81-7.79 (d, 1H), 7 .71-7.69(d,1H),7.63-7.59(m,2H),7.51-7.48(dd,1H),7.34-7.31(m,1H),7.11(m,1H ), 7.01-6.98(m, 2H), 5.61-5.43(m, 4H), 5.10-5.07(m, 1H), 4.89-4.83(m, 1H), 4.75-4 .71(m, 1H), 4.52-4.47(m, 1H), 4.39-4.33(m, 1H), 2.77-2.68(m, 1H), 2.43-2.37(m, 1H)

[0299] Example 131: Preparation of (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0300] Step 1) Preparation of 2-((4-chloro-2-fluorobenzyl)oxy)-6-(1H-pyrazol-4-yl)pyridine

[0301]

[0302] 2-Bromo-6-((4-chloro-2-fluorophenoxy)methyl)pyridine (2.0 g, 6.31 mmol) and tetrahydrofuran:ethanol:distilled water (4:2:1 (volume ratio); 20 mL, 10 mL, 5 mL; 35 mL in total) were added to a 250 mL three-necked flask and stirred for 5 minutes to dissolve. Then, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.34 g, 6.94 mmol), tripotassium phosphate (3.34 g, 15.77 mmol) and Pd(dppf)Cl2.CH2Cl2 (515 mg, 0.631 mmol) were added, slowly heated to 80°C, and then stirred for 8 hours using a reflux cooler. After the reaction was completed, the reaction product was cooled to room temperature for 30 minutes. Then, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate (30 mL) and distilled water (60 mL), and then the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure to remove the solvent, and column chromatography was performed under the condition of ethyl acetate: normal hexane = 4: 1 (volume ratio). The obtained compound was concentrated under reduced pressure to obtain the target compound (750 mg, 2.46 mmol, yield: 38%).

[0303] 1 H NMR (400MHz, CDCl3) δ8.07 (s, 2H), 7.62-7.57 (t, 1H), 7.49-7.45 (t, 1H), 7.14-7.09 (m, 3H), 6.64-6.62 (d, 1H), 5.48 (s, 2H)

[0304] Step 2 Preparation of (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0305]

[0306] To a 100 mL flask, 2-((4-chloro-2-fluorophenoxy)oxy)-6-(1H-pyrazol-4-yl)pyridine (750 mg, 2.46 mmol) and acetonitrile (10 mL) previously prepared in step 1 were added and stirred for 10 minutes to dissolve. (S)-2-(fluoromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (800 mg, 2.71 mmol) and calcium carbonate (1.01 g, 7.38 mmol) were added, slowly heated to 80° C., and then stirred for 3 hours using a reflux cooler. After the reaction was completed, the reaction product was cooled to room temperature for 30 minutes. Then, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate (30 mL) and distilled water (60 mL), and then the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure to remove the solvent, and column chromatography was performed under the condition of ethyl acetate: n-hexane = 2: 1 (volume ratio). The obtained compound was concentrated under reduced pressure, thereby obtaining the target compound (350 mg, 0.622 mmol, yield: 25%).

[0307] 1 H NMR (400MHz, CDCl3) δ8.13 (s, 1H), 8.08 (s, 1H), 8.01-7.98 (d, 1H), 7.96 (s, 1H), 7.8 1-7.79(d,1H),7.54-7.50(t,1H),7.44-7.40(t,1H),7.09-7.01(m,3H),6.60-6.58 (d, 1H), 5.88-5.77 (q, 2H), 5.42 (s, 2H), 5.14-5.07 (m, 1H), 4.74-4.61 (m, 2H), 4.57 -4.50(d,1H),4.47-4.39(m,1H),3.93(s,3H),2.78-2.69(m,1H),2.42-2.35(m,1H)

[0308] Step 3 Preparation of (S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0309]

[0310] To a 100 mL flask were added (S)-methyl 2-((4-(6-((4-chloro-2-fluorophenoxy)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (350 mg, 0.622 mmol) and tetrahydrofuran:methanol:distilled water (4:2:1 (volume ratio); 4 mL, 2 mL, 1 mL; 7 mL in total) previously prepared in step 2. Stir for 10 minutes to dissolve. Then, 2N potassium hydroxide aqueous solution (5 mL) was added, followed by stirring at room temperature for 4 hours. After the reaction was completed, the mixed solution was concentrated under reduced pressure. 2N hydrochloric acid aqueous solution (4 mL) was added, and the concentrate was neutralized to pH 7-8 to produce a solid compound. The obtained compound was filtered under reduced pressure and dried, thereby obtaining the target compound (250 mg, 0.456 mmol, yield: 73.35%).

[0311] 1 H NMR (400MHz, DMSO) δ8.46 (s, 1H), 8.31 (s, 1H), 8.07 (s, 1H), 7.84-7.82 (d, 1H), 7 .72-7.59(m,3H),7.45-7.42(dd,1H),7.31-7.27(m,2H),6.68-6.65(d,1H),5.9 1-5.79(q, 2H), 5.45(s, 2H), 4.94-4.92(m, 1H), 4.85-4.79(m, 1H), 4.70-4.66(m , 1H), 4.51-4.47(m, 1H), 4.39-4.34(m, 1H), 2.71-2.62(m, 1H), 2.38-2.35(m, 1H)

[0312] The following Examples 1 to 6, 8 to 59 and 61 to 103 were prepared in the same manner as Example 60, except that appropriate starting materials were used according to the structures of the compounds to be prepared.

[0313] Example 1: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0314]

[0315] 1H NMR (400MHz, MeOD) δ8.75 (s, 2H), 8.45 (s, 1H), 8.33-8.32 (d, 1H), 8.20 (d, 1H), 7.99-7.95 (m, 3H), 7.85-7.76 (m, 2H) ,7.57-7.53(t,1H),7.47-7.43(m,3H),7.27-7.22(m,2H),6.85-6.83(d,1H),6.17(s,2H),5.53(s,2H),4.83(s,2H),

[0316] Example 2: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0317]

[0318] 1 H NMR (400MHz, DMSO) δ8.15 (s, 1H), 8.04-8.02 (d, 2H), 7.81-7.77 (m, 2H), 7.64-7.55 (m, 3H), 7.49-7.29 ( m, 4H), 6.83-6.81 (d, 1H), 5.50 (s, 2H), 4.49-4.46 (t, 2H), 4.41 (s, 2H), 3.56-3.54 (m, 2H), 3.15 (s, 3H)

[0319] Example 3: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0320]

[0321] 1 H NMR (400MHz, CDCl3) δ8.15 (s, 1H), 8.03-8.02 (d, 1H), 7.82-7.69 (m, 4H), 7.34-7.30 (m, 3H), 7.14-7.11 (d, 2H), 6.76-6.74 (d, 1H), 5.50 (s, 2H), 4.48 (s, 2H), 4.37-4.35 (t, 2H), 3.65-3.62 (t, 2H), 3.25 (s, 3H)

[0322] Example 4: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0323]

[0324] 1 H NMR (400MHz, DMSO) δ12.75 (s, 1H), 8.16 (s, 1H), 7.83-7.78 (m, 2H), 7.64-7.62 (d, 1H), 7.57-7.55 (t, 1H), 7.53-7.49 (d, 1H), 7.47-7.46 (d, 1H), 7 .38-7.36(d,1H),7.32-7.13(m,3H),6.87-6.85(d,1H),5.39(s,2H),4.5 1-4.48(t, 2H), 4.36(s, 2H), 3.58-3.56(t, 2H), 3.33(s, 3H), 3.18(s, 3H)

[0325] Example 5: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0326]

[0327] 1 H NMR (400MHz, DMSO) δ8.85 (s, 1H), 8.65 (d, 1H), 8.40 (s, 1H), 7.97-7.88 (m, 4H), 7.76-7.73 (d, 1H), 7.69-7.65 (t, 1H), 7 .50-7.49(d,1H),7.35-7.33(d,1H),7.04-7.02(d,1H),5.58(s,2H),4.99-4.98(t,2H),3.87-3.84(t,2H),3.25(s,3H)

[0328] Example 6: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0329]

[0330] 1H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.93 (t, 1H), 7.83-7.80 (m, 2H), 7.64-7.62 (m, 2H), 7.57-7.43 (m, 2H), 7.33 -7.28(m, 3H), 6.90-6.88(d, 1H), 5.47(s, 2H), 4.54-4.52(t, 2H), 4.38(s, 2H), 3.61-3.59(t, 2H), 3.18(s, 3H)

[0331] Example 8: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0332]

[0333] 1 H NMR (400MHz, CDCl3) δ8.16 (s, 1H), 8.07-8.04 (d, 1H), 7.85-7.83 (d, 1H), 7.63 -7.58(m, 1H), 7.56-7.50(m, 3H), 7.40-7.31(m, 4H), 7.19-7.14(m, 2H), 6.94-6 .90(m, 1H), 5.21(s, 2H), 4.60-4.46(q, 2H), 4.26-4.14(m, 3H), 3.89-3.84(q, 1 H), 3.76-3.70(q, 1H), 2.12-1.90(m, 1H), 1.88-1.86(m, 2H), 1.57-1.52(m, 1H)

[0334] Example 9: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0335]

[0336] 1H NMR (400MHz, CDCl3) δ8.16 (s, 1H), 8.07-8.05 (d, 1H), 7.84-7.82 (d, 1H), 7.62 -7.56(m,1H),7.50-7.48(d,1H),7.39-7.32(m,3H),7.15-7.12(m,4H),6.99-6 .94(m, 1H), 5.20(s, 2H), 4.58-4.45(q, 2H), 4.43-4.12(m, 3H), 3.92-3.84(q, 1 H), 3.77-3.72(q, 1H), 2.17-2.03(m, 1H), 1.92-1.84(m, 2H), 1.60-1.55(m, 1H)

[0337] Example 10: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0338]

[0339] 1 H NMR (400MHz, DMSO) δ8.19 (s, 1H), 8.04-8.02 (d, 2H), 7.82-7.84 (t, 2H), 7.63-7.56 ( m, 3H), 7.51-7.50 (dd, 1H), 7.48-7.41 (d, 2H), 7.31-7.30 (dd, 1H), 6.84-6.82 (d, 1H ), 5.50 (s, 2H), 4.49-4.42 (m, 3H), 4.31-4.25 (q, 1H), 4.09-4.02 (m, 1H), 3.80-3.75 (q, 1H), 3.63-3.57 (q, 1H), 2.09-1.98 (m, 1H), 1.86-1.76 (m, 2H), 1.62-1.59 (m, 1H)

[0340] Example 11: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0341]

[0342] 1H NMR (400MHz, DMSO) δ8.20 (s, 1H), 7.97-7.93 (t, 1H), 7.85-7.78 (m, 2H), 7.64- 7.58(m, 2H), 7.50-7.43(m, 2H), 7.32-7.29(t, 3H), 6.90-6.88(d, 1H), 5.47(s , 2H), 4.53-4.49(m, 3H), 4.36-4.30(m, 1H), 4.12-4.06(q, 1H), 3.80-3.74(q, 1H), 3.63-3.5(q, 1H), 2.09-2.01(m, 1H), 1.87-1.76(m, 2H), 1.65-1.60(m, 1H)

[0343] Example 12: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0344]

[0345] 1 H NMR (400MHz, DMSO) δ8.25 (s, 1H), 8.05-8.02 (d, 2H), 7.82-7.80 (m, 2H), 7.65-7.56 (m, 4H), 7.49-7.48 (d, 1H), 7.44-7. 42(d,1H),7.33-7.31(m,2H),6.84-6.82(d,1H),6.45-6.44(d,1H),6.37(d,1H),5.58(s,2H),5.50(s,2H),4.47(s,2H)

[0346] Example 13: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0347]

[0348] 1 H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.84-7.78 (m, 4H), 7.66-7.60 (m, 4H), 7.51 (d, 1H), 7.49-7.48 (t, 1H), 7.44 -7.40(d,1H),6.89-6.87(d,1H),6.53-6.52(d,1H),6.42-6.41(d,1H),5.69(s,2H),5.52(s,2H),4.50(s,2H)

[0349] Example 14: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0350]

[0351] 1 H NMR (400MHz, MeOD) δ8.28 (s, 1H), 7.98-7.96 (dd, 1H), 7.81-7.78 (t, 1H), 7.6 6-7.62(m,3H),7.48-7.40(m,3H),7.38-7.28(m,3H),7.06-7.04(d,1H),7.3 5(s, 2H), 5.3(s, 2H), 4.54-4.48(m, 3H), 4.36-4.20(m, 2H), 3.93-3.88(m, 1H ), 3.76-3.71(m, 1H), 2.17-2.11(m, 1H), 2.00-1.89(m, 2H), 1.74-1.69(m, 1H)

[0352] Example 15: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0353]

[0354] 1 H NMR (400MHz, MeOD) δ8.23 (s, 1H), 7.98-7.96 (dd, 1H), 7.81-7.61 (m, 6H), 7.55-7.43(m, 2H), 7.30-7.28(t, 1H), 6.85-6.82(d, 1H), 5.65(s, 1H), 4.5 7-4.52(d,1H),4.46-4.41(d,2H),4.30-4.17(m,2H),3.95-3.89(m,2H),3 .75-3.70(q, 1H), 2.17-2.09(m, 1H), 1.95-1.88(m, 2H), 1.71-1.68(m, 1H)

[0355] Example 16: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0356]

[0357] 1 H NMR (400MHz, CDCl3) δ8.19 (s, 1H), 8.06-8.04 (d, 1H), 7.84-7.82 (d, 1H), 7.47 -7.43(t, 1H), 7.37-7.26(m, 4H), 7.17-7.11(m, 4H), 6.95-6.93(d, 1H), 5.11(s , 2H), 4.53-4.33(q, 2H), 4.33-4.29(m, 1H), 4.27-4.16(m, 2H), 3.94-3.85(q, 1 H), 3.76-3.70(q, 1H), 2.12-2.03(m, 1H), 1.92-1.85(m, 2H), 1.65-1.60(m, 1H)

[0358] Example 17: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0359]

[0360] 1 H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.93-7.77 (m, 4H), 7.66-7.56 (m, 3H), 7.51-7.39 (m, 2H), 7.33-7.31 (d, 1H), 6.89-6.87 (d, 1H), 5.52 (s, 2H), 4.55-4.33(m, 4H), 4.18-4.14(d, 1H), 3.82-3.76(q, 1H), 3.66-3.60(q, 1H), 2.11-2.03(m, 1H), 1.88-1.77(m, 2H), 1.66-1.61(m, 1H)

[0361] Example 18: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0362]

[0363] 1H NMR (400MHz, DMSO) δ8.27 (s, 1H), 7.84-7.59 (m, 10H), 7.43-7.41 (d, 2H), 6.88 (d, 1H), 6.45 (d, 1H), 6.38 (d, 1H), 5.62-5.60 (d, 4H), 4.48 (s, 2H)

[0364] Example 19: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0365]

[0366] 1 H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.84-7.58 (m, 10), 7.43-7.41 (t, 1H), 6.94- 6.90 (d, 1H), 6.53 (s, 1H), 6.41 (s, 1H), 5.69 (s, 2H), 5.58 (s, 2H), 4.49 (s, 2H)

[0367] Example 20: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0368]

[0369] 1 H NMR (400MHz, MeOD) δ8.24 (s, 1H), 8.00-7.97 (d, 3H), 7.75-7.49 (m, 6H), 7.37-7.35 (d, 2 H), 6.83-6.81(d, 1H), 5.63(s, 2H), 4.49(s, 2H), 4.44(t, 2H), 3.59(t, 2H), 3.23(s, 3H)

[0370] Example 21: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0371]

[0372] 1H NMR (400MHz, MeOD) δ8.24 (s, 1H), 8.00 (d, 1H), 7.78-7.59 (m, 6H), 7.39-7.3 (m, 3H), 7.25-7.22 (m, 2 H), 7.02-6.99(d, 1H), 5.29(s, 2H), 4.48(s, 2H), 4.45-4.43(t, 2H), 3.61-3.58(t, 2H), 3.24(s, 3H)

[0373] Example 22: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0374]

[0375] 1 H NMR (400MHz, DMSO) δ12.76 (s, 1H), 8.16 (s, 1H), 7.81-7.79 (d, 1H), 7.63 (s, 4H), 7.52-7.24 (m, 7H), 7.02-7.00 (d, 1H), 5.21 (s, 2H), 4.49 (s, 2H), 4.39 (s, 2H), 3.56 (s, 2H), 3.16 (s, 3H)

[0376] Example 23: Preparation of 1-(furan-2-ylmethyl)-2-((5-(3-(3-methoxybenzyloxy)phenyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0377]

[0378] 1 H NMR (400MHz, CDCl3) δ8.74 (d, 1H), 8.18 (s, 1H), 8.03-8.01 (d, 1H), 7.81-7.78 (m, 2H), 7.42-7.35 (m, 2H), 7.30-7.28 (m, 2H), 7. 14-7.12(d,2H),7.02-7.00(m,3H),6.88-6.85(dd,1H),6.25-6.21(m,2H),5.51(s,2H),5.09(s,2H),4.70(s,2H),3.81(s,3H)

[0379] Example 24: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0380]

[0381] 1 H NMR (400MHz, CDCl3) δ8.17 (s, 1H), 8.08-8.05 (d, 1H), 7.86-7.84 (d, 1H), 7.52-7.44 (m, 3H), 7.35-7.31 (t, 3H), 7.17-7.10 (m, 4H), 6.93-6 .91(d,1H),5.12(s,2H),4.61-4.47(m,2H),4.22-4.09(m,3H),3.89- 3.70(m, 2H), 2.04-1.99(m, 1H), 1.89-1.82(m, 2H), 1.57-1.52(m, 1H)

[0382] Example 25: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0383]

[0384] 1 H NMR (400MHz, DMSO) δ8.26-8.23 (d, 1H), 7.95-7.57 (m, 9H), 7.46-7.30 (m, 1H), 7.00-6. 92(m,1H),5.62(s,2H),4.61-4.60(m,2H),4.59-4.40(d,2H),3.86(t,2H),3.20(s,3H)

[0385] Example 26: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0386]

[0387] 1 H NMR (400MHz, DMSO) δ8.36 (s, 1H), 7.95-7.92 (d, 2H), 7.81-7.75 (m, 2H), 7.71-7.57 (m, 3H), 7.49-7.40 (m, 3 H), 7.36-7.34(d, 1H), 7.10-7.08(dd, 1H), 5.35(s, 2H), 4.70(s, 2H), 4.48(s, 2H), 3.70(t, 2H), 3.38(s, 3H)

[0388] Example 27: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0389]

[0390] 1 H NMR (400MHz, DMSO) δ8.25 (s, 1H), 7.95-7.92 (dd, 1H), 7.82-7.78 (m, 2H), 7.75-7.73 (m, 1H), 7.67-7.62 (m, 3H), 7.58 (s, 1H), 7.41-7.39(d, 3H), 7.31-7.25(m, 2H), 7.05-7.02(dd, 1H), 6.43-6.37(d, 2H), 5.62(s, 2H), 5.33(s, 1H), 4.46(s, 2H)

[0391] Example 28: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0392]

[0393] 1 H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.95-7.93 (d, 1H), 7.83-7.74 (m, 3H), 7.67-7.54 (m, 3H), 7.51-7.49 (dd, 1H), 7. 44-7.37(m, 3H), 7.34-7.31(m, 1H), 7.09(d, 1H), 6.52(s, 1H), 6.41(s, 1H), 5.69(s, 2H), 5.35(s, 2H), 4.48(s, 2H)

[0394] Example 29: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-methylbiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0395]

[0396] 1H NMR (400MHz, CDCl3) δ8.23 (s, 1H), 8.08-8.05 (dd, 1H), 7.85-7.83 (d, 1H), 7.72-7.68 (t, 1H), 7.50-7.48 (dd, 1H), 7.3 9-7.31 (m, 3H), 7.16 (s, 3H), 6.95-6.87 (m, 3H), 6.29-6.28 (m, 1H), 6.16 (d, 1H), 5.26 (s, 2H), 5.19 (s, 2H), 4.47 (s, 2H)

[0397] Example 30: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0398]

[0399] 1 H NMR (400MHz, CDCl3) δ8.22 (s, 1H), 8.07-8.05 (dd, 1H), 7.84-7.82 (d, 1H), 7.69-7.60 (m, 2H), 7.45-7.43 (dd, 1H), 7.37-7.33 (m , 3H), 7.18-7.16(m, 2H), 7.02-7.01(d, 1H), 6.79(d, 1H), 6.29-6.27(m, 1H), 6.18(d, 1H), 5.52(s, 2H), 5.24(s, 2H), 4.47(s, 2H)

[0400] Example 31: Preparation of 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0401]

[0402] 1 H NMR (400MHz, DMSO) δ8.35 (s, 1H), 8.03-7.91 (m, 5H), 7.69-7.67 (d, 1H), 7.53-7.47 (m, 3H), 7.35-7. 31(t, 1H), 7.24-7.21(m, 1H), 5.37(s, 2H), 4.69(s, 2H), 4.58(s, 2H), 3.69-3.67(t, 2H), 3.20(s, 3H)

[0403] Example 32: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0404]

[0405] 1 H NMR (400MHz, DMSO) δ8.32 (s, 1H), 8.31 (s, 1H), 7.82-7.77 (dd, 1H), 7.66-7.49 (m, 5H), 7. 43-7.31(m, 5H), 7.26(s, 1H), 7.07-7.04(dd, 1H), 5.83(s, 2H), 5.23(s, 2H), 4.48(s, 2H)

[0406] Example 33: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0407]

[0408] 1 H NMR (400MHz, DMSO) δ8.31-8.22 (d, 2H), 7.84-7.81 (dd, 1H), 7.67-7.60 (m, 2H), 7.52-7.45 (m, 2H), 7.42-7. 33(m, 2H), 7.28-7.21(m, 2H), 7.17-7.13(m, 3H), 7.08-7.05(dd, 1H), 5.79(s, 2H), 5.18(s, 2H), 4.49(s, 2H)

[0409] Example 34: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0410]

[0411] 1H NMR (400MHz, DMSO) δ8.33 (s, 1H), 8.31 (s, 1H), 7.92-7.79 (m, 4H), 7.66-7.59 (m, 3H), 7.51-7.50 (dd, 1H), 7.49-7.40(t, 1H), 7.34-7.31(dd, 1H), 6.89-6.87(d, 1H), 5.83(s, 2H), 5.52(s, 2H), 4.50(s, 2H)

[0412] Example 35: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0413]

[0414] 1 H NMR (400MHz, DMSO) δ8.30 (s, 1H), 8.27 (s, 1H), 7.95-7.91 (t, 1H), 7.84-7.82 (t, 2H), 7.67-7.65 (m, 1H), 7.60 ( t, 1H), 7.49 (dd, 1H), 7.44 (dd, 1H) 7.33-7.27 (m, 3H), 6.90-6.88 (d, 1H), 5.79 (s, 2H), 5.47 (s, 2H), 4.51 (s, 2H)

[0415] Example 36: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0416]

[0417] 1 H NMR (400MHz, DMSO) δ8.19 (s, 1H), 7.80-7.77 (dd, 1H), 7.65-7.57 (m, 3H), 7.53-7.50 (m, 2H), 7.42-7.31 ( m, 5H), 7.06-7.04 (dd, 1H), 5.23 (s, 2H), 4.57-4.54 (t, 2H), 4.40 (s, 2H), 3.67-3.64 (t, 2H), 3.20 (s, 3H)

[0418] Example 37: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0419]

[0420] 1 H NMR (400MHz, DMSO) δ12.79 (br s, 1H), 8.19 (s, 1H), 7.90-7.85 (t, 3H), 7.77-7.70 (t.2H), 7.64-7.60 (t, 1H), 7.54-7.49 (m, 2H), 7.34-7.3 2(dd, 1H), 6.94-6.92(d, 1H), 5.54(s, 2H), 4.64-4.62(t, 2H), 4.44(s, 2H), 3.73-3.70(t, 2H), 3.24(s, 3H)

[0421] Example 38: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0422]

[0423] 1 H NMR (400MHz, MeOD-d4) δ8.63 (s, 1H), 8.30-8.27 (dd, 1H), 8.08-8.03 (t, 1H), 7.85-7.81 (m.2H), 7.75-7.71 (t, 1H), 7.62-7.5 2(m, 3H), 7.36-7.33(d, 2H), 6.95-6.91(d, 1H), 5.52(s, 2H), 4.88-4.86(m, 2H), 4.81(s, 2H), 3.92-3.84(t, 2H), 3.33(s, 3H)

[0424] Example 39: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0425]

[0426] 1H NMR (400MHz, CDCl3) δ8.52 (s, 1H), 8.22-8.19 (dd, 1H), 7.80-7.77 (d, 1H), 7.58-7.54 (m.2H), 7.43-7.39 (t, 1H), 7.29-7.25 (m, 4H), 7.19-7.17 (m, 2H), 7.08-7.06 (m, 1H), 5.18 (s, 2H), 4.77-4.75 (t, 2H), 4.71 (s, 2H), 3.81-3.79 (t, 2H), 3.30 (s, 3H)

[0427] Example 40: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0428]

[0429] 1 H NMR (400MHz, MeOD-d4) δ8.33 (s, 1H), 8.06-8.04 (dd, 1H), 7.80-7.69 (m, 3H), 7.64-7.61 (m.1H), 7.52-7.48 (m, 1H), 7.42- 7.38(m, 1H), 7.21-7.17(m, 4H), 7.07-7.05(m, 1H), 5.31-5.26(m, 2H), 4.57-4.53(m, 4H), 3.71-3.68(t, 2H), 3.27(s, 3H)

[0430] Example 41: Preparation of (R)-2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0431]

[0432] 1H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.80-7.77 (dd, 1H), 7.66-7.60 (m, 3H), 7.54-7.51 (m.2H), 7.43-7.31 (m, 5H), 7.07-7.04 (m, 1H), 5.23 ( s, 2H), 4.56-4.33 (m, 4H), 4.18-4.13 (m, 1H), 3.82-3.77 (q, 1H), 3.77 -3.61(q, 1H), 2.10-2.04(m, 1H), 1.88-1.79(m, 2H), 1.66-1.58(m, 1H)

[0433] Example 42: Preparation of (R)-2-((3′-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0434]

[0435] 1 H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.81-7.79 (dd, 1H), 7.64-7.60 (m, 2H ), 7.53-7.49(m.2H), 7.43-7.24(m, 4H), 7.18-7.14(m, 2H), 7.08-7.06(dd, 1H), 5.19(s, 2H), 4.53-4.30(m, 4H), 4.10-4.08(m, 1H), 3.80-3.75(q, 1H), 3.63-3.58(q, 1H), 2.07-2.03(m, 1H), 1.88-1.78(m, 2H), 1.63-1.61(m, 1H)

[0436] Example 43: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0437]

[0438] 1H NMR (400MHz, DMSO-d6) δ8.20 (s, 1H), 7.96-7.89 (m, 2H), 7.87-7.79 (m, 2H), 7.68-7.55 (m.3H), 7.52-7.4 2(m, 2H), 7.36-7.30(d, 1H), 6.89-6.87(d, 1H), 5.53(s, 2H), 4.83-4.78(m, 2H), 4.71(s, 2H), 4.41(s, 2H)

[0439] Example 44: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0440]

[0441] 1 H NMR (400MHz, DMSO-d6) δ8.18 (s, 1H), 7.94-7.83 (m, 4H), 7.80-7.72 (m, 3H), 7.70-7.66 (d.1H), 7.52-7.42(m, 1H), 6.94-6.92(d, 1H), 5.62(s, 2H), 4.83-4.77(m, 2H), 4.71(s, 2H), 4.41(s, 2H)

[0442] Example 45: Preparation of (R)-2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0443]

[0444] 1 H NMR (400MHz, CDCl3) δ8.26 (s, 1H), 8.02-7.91 (m, 4H), 7.80-7.78 (dd.1H), 7.60-7.58(d, 1H), 7.52-7.44(m, 3H), 7.36-7.31(t, 1H), 7.24-7.21(m, 1H ), 5.37(s, 2H), 4.57-4.34(m, 4H), 4.19-4.15(m, 1H), 3.82-3.77(q, 1H), 3 .66-3.61(q, 1H), 2.10-2.04(m, 1H), 1.89-1.80(m, 2H), 1.67-1.63(m, 1H)

[0445] Example 46: Preparation of (R)-2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0446]

[0447] 1 H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 8.08-7.93 (m, 1H), 7.83-7.67 (m, 4H), 7.61-7.51(m.3H), 7.44-7.39(m, 3H), 7.35-7.32(m, 1H), 7.08-7.06(m, 1H), 5.35-5.30(m, 2H), 4.56-4.35(m, 4H), 4.16-4.14(m, 1H), 3.82-3.77(q, 1H) , 3.66-3.62(q, 1H), 2.10-2.05(m, 1H), 1.88-1.80(m, 2H), 1.67-1.60(m, 1H)

[0448] Example 47: Preparation of (R)-2-((3′-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0449]

[0450] 1 H NMR (400MHz, DMSO-d6) δ8.20 (s, 1H), 8.08-7.92 (m, 1H), 7.81-7.61 (m, 5H), 7.58-7.49 (m .2H), 7.43-7.39(m, 1H), 7.31-7.24(m, 2H), 7.21-7.13(m, 2H), 7.12-7.07(m, 1H), 5.30- 5.25(m, 2H), 4.53-4.50(m, 1H), 4.43(s, 2H), 4.39-4.32(m, 1H), 4.14-4.10(m, 1H), 3.80 -3.75(q, 1H), 3.63-3.58(q, 1H), 2.09-2.00(m, 1H), 1.79-1.77(m, 2H), 1.62-1.58(m, 1H)

[0451] Example 48: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3,5-difluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0452]

[0453] 1 H NMR (400MHz, CDCl3) δ8.19 (s, 1H), 8.09-8.07 (m, 1H), 7.91-7.89 (m.1H), 7.49-7.45 (t, 1H), 7.35-7.32 (t, 1H), 7. 19-7.10(m, 6H), 6.99-6.96(m, 1H), 5.12(s, 2H), 4.62(brs, 2H), 4.47-4.45(m, 2H), 3.73-3.70(t, 2H), 3.29(s, 3H)

[0454] Example 49: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0455]

[0456] 1 H NMR (400MHz, DMSO-d6) δ8.25 (s, 1H), 7.91-7.79 (m, 4H), 7.66-7.60 (m, 3H), 7.51-7.48 (dd.1H), 7.46-7.41 (m, 2H), 7.34-7.31(m, 1H), 7.14-7.13(d, 1H), 7.00-6.97(t, 1H), 6.90-6.87(d, 1H), 5.88(s, 2H), 5.52(s, 2H), 4.47(s, 2H)

[0457] Example 50: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0458]

[0459] 1H NMR (400MHz, DMSO-d6) δ8.26 (s, 1H), 7.94-7.90 (t, 1H), 7.86-7.81 (m, 2H), 7.68-7.66 (d, 1H), 7.64-7.58 (t, 1H), 7.51-7.48 (dd, 1H), 7.43-7.40(m, 2H), 7.33-7.25(m, 3H), 7.07-7.06(d, 1H), 6.96-6.93(m, 1H), 6.90-6.88(d, 1H), 5.86(s, 2H), 5.47(s, 2H), 4.49(s, 2H)

[0460] Example 51: Preparation of (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0461]

[0462] 1 H NMR (400MHz, DMSO-d6) δ8.23 (s, 1H), 7.94-7.78 (m, 4H), 7.66-7.58 (m, 3H), 7.52-7.43 (m, 2H), 7.34-7.31 (dd, 1H), 6.90-6.88 (d, 1H), 5.52 ( s, 2H), 4.58-4.37 (m, 4H), 4.19-4.13 (m, 1H), 3.82-3.77 (q, 1H), 3.66 -3.60(q, 1H), 2.10-2.04(m, 1H), 1.89-1.78(m, 2H), 1.67-1.60(m, 1H)

[0463] Example 52: Preparation of (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0464]

[0465] 1H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.98-7.94 (t, 1H), 7.89-7.79 (m, 2H) ,7.64-7.58(m,2H),7.53-7.43(m,2H),7.34-7.29(m,3H),6.91-6.89(d,1 H), 5.47(s, 2H), 4.54-4.31(m, 4H), 4.13-4.07(m, 1H), 3.80-3.75(q, 1H), 3.63-3.58(q, 1H), 2.09-2.00(m, 1H), 1.88-1.78(m, 2H), 1.65-1.58(m, 1H)

[0466] Example 53: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0467]

[0468] 1 H NMR (400MHz, MeOD-d4) δ8.61 (s, 1H), 8.27-8.25 (d, 1H), 8.04 (s, 1H), 7.97-7.95 (d.1H), 7.80-7.76 (m, 2H), 7.57-7.53 (m, 2H), 7.35-7.3 3(m, 2H), 7.26-7.21(m, 2H), 6.85-6.83(d, 1H), 5.56(s, 2H), 4.86-4.85(m, 2H), 4.79(s, 2H), 3.88-3.87(m, 2H), 3.33(s, 3H), 2.41(s, 3H)

[0469] Example 54: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0470]

[0471] 1H NMR (400MHz, DMSO-d6) δ8.19 (s, 1H), 8.05-7.65 (m, 7H), 7.59-7.52 (m, 2H), 7.17-7.15 (d, 1H), 6.8 8-6.84(m,1H),5.61-5.57(m,2H),4.51(s,2H),4.38(s,2H),3.63(s,2H),3.20(s,3H),2.33(s,3H)

[0472] Example 55: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0473]

[0474] 1 H NMR (400MHz, MeOD-d4) δ8.39 (s, 1H), 8.11-8.04 (m, 2H), 7.78-7.74 (m, 2H), 7.56-7.47 (m.2H), 7.2 9-7.20(m, 4H), 6.85-6.83(d, 1H), 5.50(s, 2H), 4.93-4.81(m, 2H), 4.76-4.72(m, 2H), 4.59(s, 2H)

[0475] Example 56: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0476]

[0477] 1 H NMR (400MHz, DMSO-d6) δ8.19 (s, 1H), 7.82-7.79 (d, 1H), 7.68-7.57 (m, 3H), 7.56-7.50 (m, 2H), 7.47-7.30(m, 5H), 7.07-7.04(d, 1H), 5.23(s, 2H), 4.84-4.83(m, 2H), 4.80(s, 2H), 4.40(s, 2H)

[0478] Example 57: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0479]

[0480] 1 H NMR (400MHz, DMSO-d6) δ8.22 (s, 1H), 7.96-7.93 (d, 1H), 7.87-7.79 (m, 3H), 7.61-7.59 (d, 2H), 7.59-7.58 (d, 1H), 7.47-7.44(m, 3H), 7.35-7.33(d, 1H), 7.09-7.07(d, 1H), 5.35(s, 2H), 4.84-4.83(m, 2H), 4.80(s, 2H), 4.40(s, 2H)

[0481] Example 58: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0482]

[0483] 1 H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.99-7.81 (m, 4H), 7.77-7.72 (m, 2H), 7.67-7.64 (d, 1H), 7.5 0-7.45(m, 2H), 7.33-7.27(m, 2H), 6.95-6.93(d, 1H), 5.57(s, 2H), 4.77-4.66(m, 2H), 4.43(s, 2H)

[0484] Example 59: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0485]

[0486] 1 H NMR (400MHz, MeOD-d4) δ8.21 (s, 1H), 7.93-7.77 (m, 4H), 7.66-7.57 (m, 3H), 7.51-7.42 (m.2H), 7.33-7.30 (dd, 1H), 6.90 (d, 1H), 5.52 (s, 2H), 4.56-4.33(m, 4H), 4.19-4.13(m, 1H), 3.82-3.77(q, 1H), 3.66-3.60(q, 1H), 2.10-2.05(m, 1H), 1.88-1.79(m, 2H), 1.69-1.58(m, 1H)

[0487] Example 61: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0488]

[0489] 1 H NMR (400MHz, DMF-d6) δ8.41 (s, 1H), 8.34-8.30 (m, 2H), 8.23-8.19 (t, 1H), 8.11-8.09 (d, 1H), 8.05-8.01(t, 1H), 7.93-7.91(d, 2H), 7.79-7.74(m, 2H), 7.40-7.38(d, 1H), 5.90(s , 2H), 5.11-5.04(m, 4H), 4.94-4.88(m, 2H), 4.63-4.61(m, 2H), 4.50-4.40(m, 2H), 4.25- 4.20(q, 1H), 4.09-4.03(q, 1H), 2.56-2.49(m, 1H), 2.33-2.24(m, 2H), 2.12-2.05(m, 1H)

[0490] Example 62: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0491]

[0492] 1 H NMR (400MHz, MeOD-d4) δ8.49 (s, 1H), 8.16-8.14 (d, 1H), 7.87-7.70 (m, 4H), 7.6 6-7.57(m.2H), 7.53-7.50(d, 1H), 7.30-7.27(t, 1H), 6.97-6.95(d, 1H), 5.62( s, 2H), 4.81-4.70 (m, 3H), 4.57-4.51 (m, 1H), 4.33-4.28 (m, 1H), 3.98-3.90 (m, 1H), 3.79-3.70(m, 1H), 2.27-2.20(m, 1H), 2.00-1.95(m, 2H), 1.81-1.76(m, 1H)

[0493] Example 63: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0494]

[0495] 1 H NMR (400MHz, DMSO-d6) δ8.41 (s, 1H), 7.97-7.95 (d, 1H), 7.85-7.81 (t, 1H), 7.72-7.64 (m , 4H), 7.61-7.57(t, 1H), 7.51-7.48(dd, lH), 7.39-7.37(d, 1H), 7.33-7.30(d, 1H), 6.89- 6.87(d,1H),5.34(s,2H),4.68-4.43(m,4H),4.16-4.13(m,1H),3.86-3.76(m,4H),3.67 -3.61(q, 1H), 3.48-3.38(q, 1H), 2.12-2.04(m, 1H), 1.94-1.79(m, 2H), 1.71-1.62(m, 1H)

[0496] Example 64: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0497]

[0498] 1 H NMR (400MHz, MeOD-d4) δ8.58 (s, 1H), 8.25-8.23 (d, 1H), 7.84-7.75 (m, 2H), 7. 75-7.72(m, 3H), 7.69-7.55(m, 2H), 7.50-7.48(d, 1H), 6.92-6.89(d, 2H), 5.6 8(s, 2H), 4.75-4.58(m, 4H), 4.29-4.24(m, 1H), 3.99-3.91(m, 1H), 3.86(s, 3H ), 3.80-3.74(m, 1H), 2.26-2.17(m, 1H), 2.05-1.93(m, 2H), 1.83-1.74(m, 1H)

[0499] Example 65: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0500]

[0501] 1 H NMR (400MHz, CDCl3) δ8.16 (s, 1H), 7.99-7.96 (dd, 2H), 7.76-7.74 (d.13H), 7.65-7.57(m, 3H), 7.47-7.43(t, 1H), 7.27-7.25(m, 2H), 7.14-7.11(d, 2H), 6.78-6.76(d,1H),4.49-4.42(m,3H),4.34-4.24(m,2H),3.94-3.88(q,1H) , 3.80-3.75(q, 1H), 2.17-2.05(m, 1H), 1.96-1.86(m, 2H), 1.69-1.62(m, 1H)

[0502] Example 66: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0503]

[0504] 1 H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.94-7.79 (m, 4H), 7.79-7.72 (m, 3H) ,7.72-7.65(d,1H),7.59-7.56(d,1H),7.45-7.41(t,1H),6.94-6.92(d,1 H), 5.62 (s, 2H), 4.57-4.33 (m, 4H), 4.18-4.12 (m, 1H), 3.82-3.76 (q, 1H), 3.65-3.60(q, 1H), 2.11-2.03(m, 1H), 1.88-1.66(m, 2H), 1.66-1.58(m, 1H)

[0505] Example 67: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0506]

[0507] 1 H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.95-7.84 (m, 4H), 7.81-7.79 (dd, 1H), 7.77-7 .71(m,1H),7.64-7.61(d,1H),7.48-7.44(m,1H),7.32-7.28(m,2H),6.95-6.93(d,1 H), 5.57 (s, 2H), 4.53-4.44 (m, 3H), 4.36-4.34 (m, 1H), 4.12-4.06 (m, 1H), 3.80-3.7 4(q, 1H), 3.63-3.57(q, 1H), 2.09-2.01(m, 1H), 1.89-1.74(m, 2H), 1.65-1.57(m, 1H)

[0508] Example 68: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0509]

[0510] 1 H NMR (400MHz, DMSO-d6) δ8.20 (s, 1H), 7.94-7.71 (m, 5H), 7.58-7.51 (m, 2H), 7.18-7.16 (d, 1H), 6.94-6.84 (m, 1H), 5.61 (s, 2H), 4.50-4.44 (d, 1 H), 4.39 (s, 2H), 4.33-4.27 (m, 1H), 3.86-3.78 (m, 1H), 3.69-3.61 (m, 1H ), 2.33(s, 3H), 2.09-2.00(m, 1H), 1.91-1.80(m, 2H), 1.65-1.58(m, 1H)

[0511] Example 69: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0512]

[0513] 1H NMR (400MHz, DMF-d6) δ8.62 (s, 1H), 8.32 (s, 1H), 8.26-8.19 (m, 3H), 8.0 5-7.98(m,3H),7.93-7.90(d,1H),7.75-7.73(d,1H),7.26-7.24(d,1H), 5.94(s, 2H), 4.89-4.70(m, 4H), 4.58-4.52(m, 1H), 4.25-4.22(q, 1H), 4. 08-4.03(q, 1H), 2.52-2.45(m, 1H), 2.33-2.21(m, 2H), 2.19-2.07(m, 1H)

[0514] Example 70: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0515]

[0516] 1 H NMR (400MHz, MeOD-d4) δ8.24 (s, 1H), 7.99-7.97 (d, 1H), 7.85-7.80 (m, 1H), 7.73-7. 71(d,1H),7.68-7.66(d,1H),7.53-7.49(m,2H),7.21-7.18(m,2H),7.12-7.08(d,1 H), 6.84-6.82 (d, 1H), 5.51 (s, 2H), 4.51-4.42 (m, 3H), 4.34-4.24 (m, 2H), 3.90-3.8 5(q, 1H), 3.76-3.71(q, 1H), 2.19-2.14(m, 1H), 2.03-1.89(m, 2H), 1.72-1.67(m, 1H)

[0517] Example 71: Preparation of 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0518]

[0519] 1H NMR (400MHz, DMF-d6) δ8.65 (s, 1H), 8.36-8.32 (m, 2H), 8.20-8.12 (m, 4H), 8.08-8.0 0 (m, 1H), 7.96-7.94 (d, 1H), 7.83-7.78 (m, 1H), 7.42-7.40 (d, 1H), 6.02 (s, 2H), 5.0 0-4.92 (m, 1H), 4.88-4.78 (m, 2H), 4.60-4.58 (m, 1H), 4.30-4.29 (d, 1H), 4.23-4.20 (m, 1H), 4.08-4.02 (m, 1H), 2.53-2.47 (m, 1H), 2.33-2.21 (m, 2H), 2.11-2.03 (m, 1H)

[0520] Example 72: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0521]

[0522] 1 H NMR (400MHz, DMSO-d6) δ8.17 (s, 1H), 7.89-7.79 (m, 4H), 7.67-7.60 (m, 4H), 7.51-7.49 (dd, 1H), 7.43-7.39 (t, 1H), 7.34-7.32(dd, 1H), 6.89-6.87(d, 1H), 6.47(s, 2H), 5.72(s, 2H), 5.52(s, 2H), 4.04-3.94(q, 2H), 1.20-1.15(t, 3H)

[0523] Example 73: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0524]

[0525] 1H NMR (400MHz, DMSO-d6) δ8.25 (s, 1H), 7.94-7.83 (m, 4H), 7.80-7.72 (m, 3H), 7.67-7.66 (m, 1H), 7.59-7.57 (d, 1H), 7.45-7.41 (t, 1 H), 6.94-6.90(m, 1H), 5.62(s, 2H), 5.05-5.03(m, 1H), 4.76-4.70(m, 1H), 4.58-4.45(m, 5H), 2.72-2.68(m, 1H), 2.40-2.34(m, 1H)

[0526] Example 74: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0527]

[0528] 1 H NMR (400MHz, DMSO-d6) δ8.24 (s, 1H), 7.93-7.84 (m, 4H) 7.82-7.79 (dd, 1H), 7. 77-7.71 (m, 1H), 7.63 (d, 1H), 7.47-7.45 (m, 1H), 7.32-7.28 (m, 2H), 6.95-6.9 3(d, 1H), 5.58(s, 2H), 5.02-4.96(m, 1H), 4.73-4.68(m, 1H), 4.59-4.54(m, 1H ), 4.51-4.48(m, 3H), 4.38-4.33(m, 1H), 2.71-2.63(m, 1H), 2.41-2.35(m, 1H)

[0529] Example 75: Preparation of 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0530]

[0531] 1H NMR (400MHz, DMSO) δ12.97 (br s, 1H), 8.21 (s, 1H), 7.91-7.77 (m, 4H), 7.64-7.63 (d, 1H), 7.59-7.57 (d, 1H), 7.54-7.52 (d, 2H), 7.46-7.41 (m, 3H), 6.90-6.88 (d, 1H), 5.49 (s, 2H), 4.55-4.33 (m, 4H), 4.18-4.16 (m, 1H), 3.82-3.77 (m, 1H), 3.66 -3.61(m, 1H), 3.09-2.03(m, 1H), 1.88-1.81(m, 1H), 1.65-1.60(m, 1H)

[0532] Example 76: Preparation of 2-(2-fluoro-4-(6-(4-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0533]

[0534] 1 H NMR (400MHz, DMSO) δ8.29 (s, 1H), 7.95-7.94 (d, 1H), 7.92 (s, 1H), 7.86-7.80 (m, 2H), 7.64-7.61(d, 2H), 7.49-7.45(t, 1H), 7.40-7.38(d, 2H), 7.20-7.18(d, 2H), 6.87-6. 85(d,1H),5.44(s,2H),4.58-4.39(m,4H),4.20-4.14(m,1H),3.83-3.77(m,1H),3.6 6-3.61(m, 1H), 2.30(s, 3H), 2.13-2.05(m, 1H), 1.91-1.79(m, 2H), 1.66-1.61(m, 1H)

[0535] Example 77: Preparation of 2-(2-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0536]

[0537] 1H NMR (400MHz, DMSO) δ8.39 (s, 1H), 7.94-7.84 (m, 4H), 7.77-7.66 (m, 6H), 7.66-7.48 (t, 1H), 6.96-6.94 (d, 1H), 5.60 (s, 2H), 4.69 -4.54(m, 4H), 4.15-4.14(m, 1H), 3.82-3.77(m, 1H), 3.65-3.60(m, 1H), 2.14-2.06(m, 1H), 1.91-1.79(m, 2H), 1.68-1.65(m, 1H)

[0538] Example 78: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0539]

[0540] 1 H NMR (400MHz, DMSO) δ8.25-8.24(d, 1H), 7.93-7.78(m, 4H), 7.66-7.58(m, 3H), 7.51-7.48(dd, 1H), 7.46-7.41(t, 1H), 7.34-7.31(d d, 1H), 6.90-6.87 (d, 1H), 5.56 (s, 2H), 5.07-5.02 (m, 1H), 4.76-4.70 (m, 1H), 4.62-4.33 (m, 5H), 2.73-2.66 (1H), 2.43-2.40 (m, 1H)

[0541] Example 79: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0542]

[0543] 1H NMR (400MHz, DMSO) δ8.25 (s, 1H), 7.98-7.94 (t, 1H), 7.86-7.80 (m, 2H), 7.65-7.58 (m, 2H), 7.50-7.43 (m, 2H), 7.33-7.29 (m, 3H), 6.90-6. 88(d,1H),5.47(s,2H),5.02-4.96(m,1H),4.74-4.68(m,1H),4.60-4.39(m,4H),4.37-4.33(m,1H),2.71-2.63(m,1H),2.40-2.32(m,1H)

[0544] Example 80: Preparation of 2-(2-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0545]

[0546] 1 H NMR (400MHz, DMSO) δ8.15 (s, 1H), 7.91-7.88 (m, 2H), 7.84-7.76 (m, 2H), 7.63-7.61 (d, 1H) ,7.52-7.50(d,1H),7.44-7.40(t,1H),7.33(s,1H),7.30-7.24(m,2H),7.14-7.12(m,1H) , 6.88-6.86(d, 1H), 4.52-4.30(m, 4H), 4.19-4.15(m, 1H), 3.82-3.77(m, 1H), 3.66-3.60( m, 1H), 2.32 (s, 3H), 2.11-2.03 (m, 1H), 1.90 (s, 1H), 1.88-1.78 (m, 2H), 1.67-1.65 (m, 1H)

[0547] Example 81: Preparation of 2-(2-fluoro-4-(6-(3-methoxybenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0548]

[0549] 1H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.94-7.88 (m, 3H), 7.84-7.77 (m, 2H), 7.64-7.57 ( dd, 2H), 7.45-7.41 (dd, 1H), 7.31-7.28 (dd, 1H), 7.10-7.06 (dd, 2H), 6.89-6.86 (m, 2 H), 5.46 (s, 2H), 4.56-4.50 (m, 1H), 4.45-4.42 (d, 1H), 4.38-4.33 (m, 1H), 3.82-3.7 4(m, 5H), 3.74-3.55(m, 1H), 2.10-2.05(m, 1H), 1.88-1.81(m, 2H), 1.65-1.61(m, 1H)

[0550] Example 82: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0551]

[0552] 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.91-7.87 (dd, 1H), 7.80-7.74 (m, 2H), 7.63-7.59 (m, 2H), 7.51-7.48 (m, 2H), 7.34-7.28 (m, 2H), 6.97-6 .94(d,1H),5.49(s,2H),5.10-5.05(m,1H),4.78-4.73(m,1H),4.65- 4.48(m, 4H), 4.39-4.33(m, 1H), 2.76-2.68(m, 1H), 2.43-2.38(m, 1H)

[0553] Example 83: Preparation of 2-(4-(6-(benzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-monocarboxylic acid

[0554]

[0555] 1H NMR (400MHz, DMSO) δ8.47 (s, 1H), 8.01-7.95 (m, 3H), 7.86-7.82 (dd, 1H), 7.76 -7.73(d,1H),7.67-7.65(d,1H),7.57-7.37(m,2H),7.34-7.30(m,1H),6.91-6 .89(d,1H),5.49(s,2H),4.74-4.51(m,4H),4.21-4.15(m,1H),3.83-3.78(m,1 H), 3.66-3.60(m, 1H), 2.15-2.07(m, 1H), 1.94-1.82(m, 2H), 1.70-1.67(m, 1H)

[0556] Example 84: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0557]

[0558] 1 H NMR (400MHz, DMSO) δ8.31 (s, 1H), 7.90-7.81 (m, 4H), 7.76-7.74 (d, 1H), 7.64-7.58 (m, 2H), 7.52-7.49 (m, 2H), 7.34-7.31 (m, 1H) , 6.96-6.92(m, 1H), 5.54(s, 2H), 5.15-5.10(m, 1H), 4.88-4.82(m, 1H), 4.73-4.35(m, 7H), 2.77-2.73(m, 1H), 2.45-2.33(m, 1H)

[0559] Example 85: Preparation of 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0560]

[0561] 1H NMR (400MHz, DMSO) δ8.38 (s, 1H), 7.95-7.91 (m, 3H), 7.87-7.83 (m, 1H), 7.69 -7.66(m, 2H), 7.61-7.56(m, 1H), 7.52-7.42(m, 2H), 7.37(m, 1H), 6.92-6.90 (d, 1H), 5.48 (s, 2H), 4.68-4.45 (m, 4H), 4.18-4.17 (m, 1H), 3.83-3.77 (m, 1H ), 3.66-3.60(m, 1H), 2.12-2.06(m, 1H), 1.91-1.79(m, 2H), 1.67-1.65(m, 1H)

[0562] Example 86: Preparation of (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0563]

[0564] 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.90-7.78 (m, 3H), 7.62-7.59 (m, 2H), 7.53- 7.49(m, 2H), 7.41-7.37(m, 1H), 7.34-7.32(m, 1H), 6.96-6.94(d, 1H), 5.51(s, 2H), 5.09-5.06(m, 1H), 4.79-4.73(m, 1H), 4.65-4.60(m, 1H), 4.55-4.49(m, 1 H), 4.47-4.42(m, 3H), 4.38-4.33(m, 1H), 2.72-2.71(m, 1H), 2.39-2.38(m, 1H)

[0565] Example 87: Preparation of 2-(4-(6-(4-cyanobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0566]

[0567] 1H NMR (400MHz, DMSO) δ8.39 (s, 1H), 7.94-7.85 (m, 6H), 7.70-7.66 (m, 4H), 7.52-7.48 (m, 1H), 6.96-6.94 (d, 1H), 5.60 (s, 2H), 4.66 -4.46(m, 4H), 4.19-4.15(m, 1H), 3.82-3.73(m, 1H), 3.65-3.60(m, 1H), 2.12-2.06(m, 1H), 1.92-1.81(m, 2H), 1.67-1.63(m, 1H)

[0568] Example 88: Preparation of 2-(2-fluoro-4-(6-(4-nitrobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0569]

[0570] 1 H NMR (400MHz, DMSO) δ8.43 (s, 1H), 8.26-8.24 (d, 2H), 7.98-7.86 (m, 4H), 7 .77-7.76(d,2H),7.72-7.67(m,2H),7.54-7.50(dd,1H),6.98-6.96(d,1H ), 5.65(s, 2H), 4.65-4.48(m, 5H), 4.20-4.14(m, 1H), 3.81-3.77(m, 2H), 3 .69-3.57(m, 2H), 2.11-2.08(m, 1H), 1.90-1.80(m, 2H), 1.66-1.65(m, 1H)

[0571] Example 89: Preparation of 2-(4-(6-(4-bromo-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0572]

[0573] 1H NMR (400MHz, DMSO) δ8.34 (s, 1H), 7.95-7.83 (m, 4H), 7.68-7.60 (m, 3H), 7.56-7.44 (m, 3H), 6.91-6.89 (d, 1H), 5.51 (s, 2H), 4.66 -4.43(m, 4H), 4.18-4.16(m, 1H), 3.89-3.79(m, 2H), 3.65-3.60(m, 2H), 2.12-2.07(m, 1H), 1.89-1.81(m, 2H), 1.67-1.64(m, 1H)

[0574] Example 90: Preparation of 2-(3-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0575]

[0576] 1 H NMR (400MHz, DMSO) δ12.75 (br s, 1H), 8.20 (s, 1H), 7.98-7.94 (dd, 1H), 7.84-7.79 (m, 2H), 7.64-7.61 (d, 1H), 7.4 3-7.25(m, 5H), 7.14-7.12(m, 1H), 6.89-6.87(d, 1H), 5.39(s, 2H), 4.53-4.52(m, 1H ), 4.49-4.48(m, 1H), 4.45-4.30(m, 1H), 4.11-4.09(m, 1H), 3.79-3.75(m, 1H), 3.6 3-3.60 (m, 1H), 2.31 (s, 3H), 2.06-2.0 (m, 1H), 1.85-1.79 (m, 2H), 1.63-1.60 (m, 1H)

[0577] Example 91: Preparation of 2-(4-(6-(4-chloro-2-fluorobenzyloxy)-5-fluoropyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0578]

[0579] 1H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.90-7.77 (m, 4H), 7.72-7.64 (m, 2H), 7.59-7.56 ( d, 1H), 7.53-7.50 (dd, 1H), 7.46-7.42 (dd, 1H), 7.36-7.31 (dd, 1H), 5.62 (s, 2H), 4. 56-4.49 (m, 1H), 4.45-4.42 (d, 1H), 4.40-4.33 (m, 1H), 4.17-4.13 (m, 1H), 3.82-3.7 7(m, 1H), 3.66-3.61(m, 1H), 2.12-2.05(m, 1H), 1.91-1.80(m, 2H), 1.67-1.62(m, 1H)

[0580] Example 92: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-2,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0581]

[0582] 1 H NMR (400MHz, DMSO) δ8.52 (s, 1H), 8.21-8.18 (d, 1H), 7.78-7.77 (d, 1H), 7.58-7.52 (m, 2H), 7.34-7.18 (m, 7H), 5.25 (s, 2H), 4.76-4.72 (m, 3H), 4.56-4.50(m, 1H), 4.29-4.27(m, 1H), 3.96-3.91(m, 1H), 3.79-3.76(m, 1H), 2.26-2.21(m, 1H), 2.02-1.97(m, 2H), 1.81-1.74(m, 1H)

[0583] Example 93: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-2,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0584]

[0585] 1H NMR (400MHz, DMSO) δ8.52 (s, 1H), 8.20-8.18 (m, 1H), 7.78-7.73 (m, 2H), 7 .70-7.68(m, 2H), 7.56-7.54(m, 1H), 7.35-7.19(m, 5H), 5.34(s, 2H), 4.75 -4.70(m, 3H), 4.56-4.50(m, 1H), 4.29-4.27(m, 1H), 3.94-3.90(m, 1H), 3 .79-3.75(m, 1H), 2.24-2.22(m, 1H), 2.20-1.96(m, 2H), 1.79-1.76(m, 1H)

[0586] Example 94: Preparation of 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0587]

[0588] 1 H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.97-7.93 (m, 1H), 7.85-7.79 (m, 2H), 7.64-7.6 2(d,1H),7.53-7.42(m,7H),7.32-7.26(m,3H),6.91-6.89(d,1H),5.44(s,2H),4 .53-4.48(m, 1H), 4.44(s, 2H), 4.36-4.30(m, 1H), 4.11-4.09(m, 1H), 3.79-3.75( m, 1H), 3.63-3.59 (m, 1H), 2.08-2.01 (m, 1H), 1.83-1.81 (m, 2H), 1.68-1.55 (m, 1H)

[0589] Example 95: Preparation of 2-((3′-(4-chloro-2-fluorobenzyloxy)-3,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0590]

[0591] 1H NMR (400MHz, DMSO) δ12.77 (s, 1H), 8.22 (s, 1H), 7.80-7.78 (d, 1H), 7.66-7.58 (m, 4H), 7.44-7.42 (m, 2H), 7.40-7.31 (m, 4H), 5.35 (s, 2H ), 4.56-4.33(m, 4H), 4.16-4.15(m, 1H), 3.81-3.77(m, 1H), 3.66-3.63(m, 1H), 2.09-2.07(m, 1H), 1.87-1.81(m, 2H), 1.65-1.62(m, 1H)

[0592] Example 96: Preparation of 2-((3′-(4-cyano-2-fluorobenzyloxy)-3,4′-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0593]

[0594] 1 H NMR (400MHz, DMSO) δ8.39 (s, 1H), 8.09 (s, 1H), 7.94-7.92 (d, 1H), 7.79-7.64 (m, 6H), 7.59-7.47 (m, 3H), 7.36-7.34 (d, 2H), 5.41 (s, 2H ), 4.69-4.46(m, 4H), 4.18-4.16(m, 1H), 3.81-3.78(m, 1H), 3.66-3.60(m, 1H), 2.11-2.09(m, 1H), 1.88-1.82(m, 2H), 1.68-1.65(m, 1H)

[0595] Example 97: Preparation of 2-(3-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0596]

[0597] 1H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.93-7.81 (m, 3H), 7.79-7.69 (m, 4H), 7.63 -7.61(d,1H),7.46-7.43(d,1H),7.32-7.26(m,1H),6.95-6.93(d,1H),5.55 (s, 2H), 4.53-4.48 (m, 1H), 4.44 (s, 2H), 4.10-4.08 (m, 1H), 3.78-3.74 (m, 1H ), 3.62-3.59(m, 1H), 2.06-2.04(m, 1H), 1.85-1.79(m, 2H), 1.62-1.60(m, 1H)

[0598] Example 98: Preparation of 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0599]

[0600] 1 H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.98-7.93 (dd, 1H), 7.86-7.79 (m, 2H), 7.64-7.62 (d , 1H), 7.59-7.54(m, 1H), 7.48-7.41(m, 2H), 7.36-7.28(m, 3H), 6.92-6.90(m, 1H), 5.4 2(s, 2H), 4.53-4.49(m, 1H), 4.45(s, 2H), 4.36-4.30(m, 1H), 4.11-4.09(m, 1H), 3.78- 3.75(m, 1H), 3.63-3.60(m, 1H), 2.04-1.91(m, 1), 1.89-1.72(m, 2H), 1.65-1.55(m, 1H)

[0601] Example 99: Preparation of 2-(4-(6-(4-chloro-3-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0602]

[0603] 1H NMR (400MHz, DMSO) δ8.25 (s, 1H), 7.94 (t, 1H), 7.87-7.82 (m, 2H), 7.66-7.58 (m , 2H), 7.53(dd, 1H), 7.44(dd, 1H), 7.37-7.29(m, 3H), 6.94-6.92(d, 1H), 5.45( s, 2H), 4.57-4.52 (m, 3H), 4.40-4.34 (m, 1H), 4.11-4.10 (m, 1H), 3.80-3.75 (m, 1H), 3.63-3.58(m, 1H), 2.09-1.99(m, 1H), 1.96-1.88(m, 2H), 1.64-1.61(m, 1H)

[0604] Example 100: Preparation of 2-(4-(6-(3-chloro-5-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0605]

[0606] 1 H NMR (400MHz, DMSO) δ8.40 (s, 1H), 7.98-7.94 (m, 2H), 7.89-7.85 (m, 1H), 7 .74-7.72(d,1H),7.47-7.33(m,6H),6.98-6.96(m,1H),5.46(s,2H),4.68 -4.61(m, 3H), 4.61-4.46(m, 1H), 4.15-4.13(m, 1H), 3.82-3.78(m, 2H), 3 .64-3.59(m, 2H), 2.08-2.07(m, 1H), 1.91-1.80(m, 2H), 1.68-1.66(m, 1H)

[0607] Example 101: Preparation of 2-(4-(6-(2-chloro-6-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0608]

[0609] 1H NMR (400MHz, DMSO) δ8.20 (s, 1H), 8.05-8.01 (m, 1H), 7.86-7.80 (m, 2H), 7.63- 7.61 (d, 1H), 7.53-7.42 (m, 3H), 7.33-7.30 (m, 3H), 6.87-6.85 (d, 1H), 5.52 (s, 2H), 4.52-4.45(m, 3H), 4.36-4.30(m, 1H), 4.11-4.10(m, 1H), 3.81-3.76(m, 1 H), 3.64-3.58(m, 1H), 2.09-2.01(m, 1H), 1.90-1.77(m, 2H), 1.65-1.61(m, 1H)

[0610] Example 102: Preparation of 2-((5-(3-(4-chloro-2-fluorobenzyloxy)-4-fluorophenyl)pyridin-2-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0611]

[0612] 1 H NMR (400MHz, DMSO) δ8.84 (s, 1H), 8.25 (s, 1H), 8.12-8.10 (d, 1H), 7.83-7.81 (d, 1H), 7.67-7.61 (m, 3H), 7.53-7.51 (m, 2H), 7.38-7.33 (m, 3H), 5.33 (s, 2H ), 4.61-4.57(m, 3H), 4.46-4.40(m, 1H), 4.14-4.13(m, 1H), 3.81-3.76(m, 1H ), 3.64-3.58(m, 1H), 2.08-2.03(m, 1H), 1.84-1.79(m, 2H), 1.63-1.58(m, 1H)

[0613] Example 103: Preparation of (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0614]

[0615] 1H NMR (400MHz, DMSO) δ8.27 (s, 1H), 7.97-7.75 (m, 8H), 7.58-7.56 (m, 1H), 7.01-6.69 (m, 1H), 5.66 (s, 2H), 5.15-5.13 (m, 1H), 4.85-4.79(m, 1H), 4.71-4.67(m, 1H), 4.60-4.40(m, 3H), 4.39-4.35(m, 1H), 2.79-2.75(m, 1H), 2.46-2.39(m, 1H)

[0616] The following Examples 104 to 109, 111 and 112 were prepared in the same manner as in Example 110, except that the starting materials were used according to the structures of the compounds to be prepared.

[0617] Example 104: Preparation of 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0618]

[0619] 1 H NMR (400MHz, DMSO) δ8.23 (s, 1H), 8.08 (s, 1H), 7.95-7.93 (d, 1H), 7.83-7.56 (m, 5H), 7.46-7.35 (m, 3H), 7.16-7. 14(m, 1H), 6.76-6.71(m, 2H), 5.47(s, 2H), 5.36-5.31(d, 2H), 4.70-4.68(m, 2H), 3.88-3.69(m, 2H), 3.24(s, 3H)

[0620] Example 105: Preparation of 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0621]

[0622] 1H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.99-7.97 (d, 1H), 7.90-7.86 (dd, 1H), 7.81-7.78 (dd, 1H), 7 .71-7.69(d,1H),7.63-7.59(m,2H),7.52-7.49(dd,1H),7.34-7.32(dd,1H),7.12-7.11(d,1H) ,7.01-6.98(m,2H),5.58-5.40(m,4H),4.68-4.67(m,1H),4.54-4.48(m,1H),4.20-4.19(m,1H) , 3.86-3.81(m, 1H), 3.67-3.62(m, 1H), 2.14-2.06(m, 1H), 1.88-1.79(m, 2H), 1.69-1.67(m, 1H)

[0623] Example 106: Preparation of 2-((4-(3-(4-chloro-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0624]

[0625] 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.95 (m, 1H), 7.80-7.79 (m, 1H), 7.76 (m, 2H), 7 .53-7.50(m,1H),7.44-7.36(m,4H),7.14(m,1H),6.74-6.71(m,2H),5.56-5.39 (m, 2H), 5.24 (s, 2H), 4.68-4.65 (m, 1H), 4.54-4.50 (m, 1H), 4.19 (m, 1H), 3.83-3 .81(m, 1H), 3.64-3.63(m, 1H), 2.10-2.09(m, 1H), 1.84(m, 2H), 1.66-1.64(m, 1H)

[0626] Example 107: Preparation of 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0627]

[0628] 1H NMR (400MHz, DMSO) δ8.26 (dd, 1H), 7.96-7.93 (m, 2H), 7.83-7.65 (m, 3H), 7.63-7.61 (m, 1H), 7. 46-7.40(m, 2H), 7.37-7.34(m, 1H), 7.17-7.13(m, 1H), 6.75-6.70(m, 2H), 5.56-5.52(d, 1H), 5 .43-5.39(d, 1H), 5.36-5.30(m, 2H), 4.68-4.64(m, 1H), 4.54-4.49(m, 1H), 4.21-4.18(m, 1H), 3.88-3.80(m, 1H), 3.67-3.61(m, 1H), 2.12-2.08(m, 1H), 1.88-1.80(m, 2H), 1.69-1.62(m, 1H)

[0629] Example 108: Preparation of (S)-2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0630]

[0631] 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.98-7.97 (d, 1H), 7.90-7.86 (dd, 1H), 7.81-7.78 (dd, 1H), 7.70-7.69(d, 1H), 7.63-7.59(m, 2H), 7.51-7.48(dd, 1H), 7.34-7.31(dd, 1H), 7.11(d, 1H), 7. 01-6.98(m, 2H), 5.58-5.40(m, 4H), 4.68-4.64(m, 1H), 4.54-4.48(m, 1H), 4.22-4.16(m, 1H), 3.86-3.80(m, 1H), 3.67-3.61(m, 1H), 2.14-2.06(m, 1H), 1.88-1.83(m, 2H), 1.70-1.60(m, 1H)

[0632] Example 109: Preparation of (S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0633]

[0634] 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.98-7.88 (m, 3H), 7.81-7.70 (m, 4H), 7. 60(d,1H),7.08(d,1H),7.03(d,1H),6.95(dd,1H),5.60-5.39(m,4H),4.6 8-4.63(m, 1H), 4.53-4.48(m, 1H), 4.22-4.16(m, 1H), 3.85-3.80(m, 1H), 3 .67-3.61(m, 1H), 2.12-2.06(m, 1H), 1.91-1.83(m, 2H), 1.69-1.58(m, 1H)

[0635] Example 111: Preparation of (S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0636]

[0637] 1 H NMR (400MHz, DMSO) δ8.28 (s, 1H), 7.98-7.86 (m, 3H), 7.82-7.60 (m, 5H), 7.10-6.95 (m, 3), 5.60-5.43 (m, 4H), 5. 12-5.06 (m, 1H), 4.88-4.70 (m, 2H), 4.52-4.47 (m, 1H), 4.38-4.33 (m, 1H), 2.77-2.68 (m, 1H), 2.43-2.39 (m, 1H)

[0638] Example 112: Preparation of 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-6-oxopyrimidin-1(6H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0639]

[0640] 1H NMR (400MHz, DMSO) δ8.80 (s, 1H), 8.23 ​​(s, 1H), 7.99-7.92 (m, 2H), 7.81-7.79 (d, 1H) ), 7.63-7.59(m, 2H), 7.50-7.48(d, 1H), 7.39-7.29(m, 2H), 7.06-7.04(d, 1H), 5.60 -5.47(m, 4H), 4.80-4.76(m, 1H), 4.68-4.59(m, 1H), 4.23-4.21(m, 1H), 3.87-3.82 (m, 1H), 3.68-3.63 (m, 1H), 2.15-2.07 (m, 1H), 1.87-1.80 (m, 2H), 1.69-1.61 (m, 1H)

[0641] The following Examples 113 to 130 and 132 to 135 were prepared in the same manner as in Example 60, except that starting materials were used according to the structures of the compounds to be prepared.

[0642] Example 113: Preparation of (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0643]

[0644] 1 H NMR (400MHz, DMSO-d6) δ8.28 (s, 1H), 7.99-7.94 (m, 2H), 7.83-7.77 (m, 4H) ,7.63-7.61(d,1H),7.54-7.52(dd,1H),7.33-7.30(t,1H),7.04-7.02(d,1 H), 5.61 (s, 2H), 5.12-5.10 (m, 1H), 4.81-4.75 (m, 1H), 4.67-4.60 (m, 2H), 4.53-4.50(m, 2H), 4.41-4.36(m, 1H), 2.77-2.73(m, 1H), 2.44-2.39(m, 1H)

[0645] Example 114: Preparation of 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0646]

[0647] 1H NMR (400MHz, DMSO-d6) δ8.28 (s, 1H), 7.97-7.88 (m, 3H), 7.84-7.83 (m, 1H) ,7.79-7.75(m,2H),7.68-7.66(d,1H),7.36-7.32(m,2H),6.99-6.97(d,1 H), 5.61 (s, 2H), 5.03-5.02 (m, 1H), 4.77-4.71 (m, 1H), 4.63-4.59 (m, 1H), 4.56-4.51(m, 3H), 4.42-4.37(m, 1H), 2.73-2.69(m, 1H), 2.43-2.38(m, 1H)

[0648] Example 115: Preparation of (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0649]

[0650] 1 H NMR (400MHz, DMSO-d6) δ8.29 (s, 1H), 7.97-7.91 (m, 2H), 7.83-7.75 (m, 4H) ,7.64-7.62(d,1H),7.57-7.55(d,1H),7.44-7.39(m,1H),7.03-7.01(d,1 H), 5.64 (s, 2H), 5.13-5.09 (m, 1H), 4.81-4.76 (m, 1H), 4.68-4.63 (m, 1H), 4.58-4.54(m, 3H), 4.41-4.36(m, 1H), 2.77-2.63(m, 1H), 2.45-2.40(m, 1H)

[0651] Example 116: Preparation of (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0652]

[0653] 1H NMR (400MHz, DMSO-d6) δ8.38 (s, 1H), 7.93-7.85 (m, 3H), 7.71-7.69 (d, 1H), 7.6 5-7.61(t, 1H), 7.56-7.49(m, 3H), 7.37-7.35(dd, 1H), 6.99-6.97(d, 1H), 5.53( s, 2H), 4.71-4.64 (m, 1H), 4.60-4.50 (m, 3H), 4.24-4.22 (m, 1H), 3.85-3.80 (q, 1H), 3.69-3.63(q, 1H), 2.89-2.84(m, 1H), 2.59-2.54(m, 2H), 1.71-1.68(m, 1H)

[0654] Example 117: Preparation of (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0655]

[0656] 1 H NMR (400MHz, DMSO-d6) δ8.30 (s, 1H), 7.98-7.94 (t, 1H), 7.86-7.82 (m, 2H), 7.69-7.63 (m, 2H), 7.55-7.48 (m, 2H), 7.38- 7.33(m, 3H), 5.59(s, 2H), 4.78-4.72(m, 1H), 4.64-4.49(m, 4H), 4.42-4.38(m, 1H), 2.55-2.53(m, 1H), 2.39-2.35(m, 1H)

[0657] Example 118: Preparation of (S)-2-(4-(6-((4-cyanobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0658]

[0659] 1H NMR (400MHz, DMSO-d6) δ8.51 (s, 1H), 8.10-8.02 (m, 6H), 7.90-7.83 (m, 4H), 7.64-7.62 (dd, 1H), 7.54-7.47 (m, 2H), 7.14-7.12 (m, 1 H), 5.72(s, 2H), 5.19-5.17(m, 1H), 4.98-4.93(m, 1H), 4.83-4.66(m, 4H), 4.57-4.55(m, 1H), 2.88-2.84(m, 1H), 2.59-2.54(m, 1H)

[0660] Example 119: Preparation of (S)-2-(4-(6-((2,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0661]

[0662] 1 H NMR (400MHz, DMSO-d6) δ8.30 (s, 1H), 8.04-8.00 (t, 1H), 7.88-7.84 (m, 2H), 7.8 0-7.64(m, 2H), 7.49-7.47(dd, 1H), 7.37-7.30(m, 3H), 7.17-7.12(m, 1H), 6.92- .6.90(d,1H),5.49(s,2H),5.04-5.01(m,1H),4.78-4.72(m,1H),4.64-4.57(m, 1H), 4.54-4.48(m, 3H), 4.41-4.37(m, 1H), 2.73-2.69(m, 1H), 2.43-2.38(m, 1H)

[0663] Example 120: Preparation of (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0664]

[0665] 1H NMR (400MHz, MeOD-d4) δ8.63 (s, 1H), 8.29-8.27 (dd, 1H), 7.88-7.76 (m, 3H), 7. 76-7.72(t,1H),7.63-7.46(m,3H),7.46-7.41(m,1H),6.99-.6.97(d,1H),5.64 (s, 2H), 4.86-4.79 (m, 2H), 4.69-4.63 (m, 1H), 4.36-4.34 (m, 1H), 3.98-3.93 (q, 1H), 3.81-3.75(q, 1H), 2.32-2.27(m, 1H), 2.10-2.00(m, 2H), 1.84-1.79(m, 1H)

[0666] Example 121: Preparation of (S)-2-(3-fluoro-4-(6-((4-(trifluoromethyl)benzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0667]

[0668] 1 H NMR (400MHz, CDCl3) δ8.14 (s, 1H), 8.09-8.07 (d, 1H), 7.98-7.94 (t, 1H), 7 .90-7.88(d,1H),7.67-7.55(m,5H),7.44-7.42(d,1H),7.20-.7.18(d,1H ), 7.12-7.09(d, 1H), 6.79-6.77(d, 1H), 5.55(s, 2H), 5.14-5.12(m, 1H), 4 .70-4.60(m, 3H), 4.44-4.30(m, 3H), 2.73-2.67(m, 1H), 2.40-2.36(m, 1H)

[0669] Example 122: Preparation of (S)-2-(3-fluoro-4-(6-((4-methoxybenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0670]

[0671] 1H NMR (400MHz, DMSO-d6) δ8.24 (s, 1H), 8.02-7.98 (t, 1H), 7.88-7.84 (m, 2H), 7.64-7.62 (m, 1H), 7.48-7.46 (d, 1H), 7.35-7.31 (m, 3H ), 7.09-7.07(m, 2H), 6.94-.6.90(m, 2H), 5.45(s, 2H), 5.04-5.01(m, 1H), 4.69-4.38(m, 6H), 2.71-2.68(m, 1H), 2.43-2.38(m, 1H)

[0672] Example 123: Preparation of (S)-2-(4-(6-((4-chlorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0673]

[0674] 1 H NMR (400MHz, DMSO-d6) δ8.43 (s, 1H), 8.15-8.11 (t, 1H), 8.03-7.97 (m, 2H), 7.8 3-7.81(d,1H),7.70-7.68(m,2H),7.64-7.60(m,3H),7.51-7.46(m,2H),7.09- 7.07(d, 1H), 5.62(s, 2H), 5.15-5.14(m, 1H), 4.91-4.86(m, 1H), 4.77-4.73(m, 1H), 4.70-4.61(m, 3H), 4.56-4.51(m, 1H), 2.87-2.83(m, 1H), 2.57-2.52(m, 1H)

[0675] Example 124: Preparation of (S)-2-(3-fluoro-4-(6-((4-nitrobenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0676]

[0677] 1H NMR (400MHz, DMSO) δ8.30-8.27 (m, 3H), 7.96-7.89 (m, 2H), 7.85 (dd, 1H), 7.79 -7.77(d,2H),7.68-7.66(d,1H),7.50(dd,1H),7.36-7.30(m,2H),7.01-6.99 (d, 1H), 5.64 (s, 2H), 5.02-5.01 (m, 1H), 4.77-4.71 (m, 1H), 4.59-4.54 (dd, 1H ), 4.52-4.46(m, 3H), 4.42-4.37(m, 1H), 2.73-2.69(m, 1H), 2.43-2.39(m, 1H)

[0678] Example 125: Preparation of (S)-2-(4-(6-((3,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0679]

[0680] 1 H NMR (400MHz, DMSO) δ8.07 (s, 1H), 8.03-7.99 (t, 1H), 7.90-7.85 (t, 1H), 7.84-7 .83(dd, 1H), 7.65-7.60(m, 1H), 7.54-7.49(m, 2H), 7.48-7.40(m, 2H), 7.36-7. 33(m, 2H), 6.98-6.95(d, 1H), 5.48(s, 2H), 5.07-5.05(m, 1H), 4.66-4.61(dd, 1 H), 4.55-4.48(m, 4H), 4.45-4.41(m, 1H), 2.75-2.70(m, 1H), 2.47-2.40(m, 1H)

[0681] Example 126: Preparation of (S)-2-(4-(6-((2-chloro-6-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0682]

[0683] 1H NMR (400MHz, DMSO) δ 8.13-8.07 (m, 2H), 7.91-7.87 (m, 2H), 7.58-7.47 (m, 4H), 7.40-7.35 (m, 3H), 6.92-6.90 (d, 1H), 5.59 ( s, 2H), 5.08-5.06 (m, 1H), 4.66-4.62 (m, 1H), 4.57-4.50 (dd, 4H), 4.45-4.40 (m, 1H), 2.75-2.71 (m, 1H), 2.47-2.42 (m, 1H)

[0684] Example 127: Preparation of 2-((6-((4-chloro-2-fluorobenzyl)oxy)-2′-oxo-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0685]

[0686] 1 H NMR (400MHz, DMSO) δ8.35 (s, 1H), 8.05-8.03 (d, 1H), 7.97-7.93 (t, 1H), 7.88-7.85 (dd, 1 H), 7.77-7.75(d, 1H), 7.69-7.65(m, 2H), 7.58-7.55(m, 1H), 7.41-7.38(dd, 1H), 7.18(s , 1H), 7.08-7.05(m, 2H), 5.67-5.48(m, 4H), 5.16-5.14(m, 1H), 4.91-4.89(m, 1H), 4.81- 4.77(d, 1H), 4.59-4.54(m, 1H), 4.44-4.40(m, 1H), 2.82-2.74(m, 1H), 2.56-2.46(m, 1H)

[0687] Example 128: Preparation of (S)-2-(3-fluoro-4-(6-(pyridin-4-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0688]

[0689] 1H NMR (400MHz, DMSO) δ8.78-8.71 (d, 2H), 8.35 (s, 1H), 8.06-8.02 (m, 2H), 7 .99-7.97(d,1H),7.76-7.74(d,1H),7.65-7.63(d,3H),7.49-7.43(m,2H) ,7.16-7.14(d,1H),5.68(s,2H),5.17-5.15(m,1H),4.87-4.81(dd,1H),4 .73-4.59(m, 4H), 4.55-4.51(m, 1H), 2.86-2.82(m, 1H), 2.55-2.52(m, 1H)

[0690] Example 129: Preparation of (S)-2-(3-fluoro-4-(6-(pyridin-3-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0691]

[0692] 1 H NMR (400MHz, DMSO) δ8.71 (s, 1H), 8.53-8.52 (d, 1H), 8.06 (s, 1H), 7.98-7.89 (m, 2H), 7.86-7.79 (m, 2H), 7.45-7.40 (m, 3H), 7.31-7.28 (m, 2H), 6. 91-6.89 (d, 1H), 5.48 (s, 2H), 5.01-4.99 (m, 1H), 4.61-4.56 (dd, 1H), 4. 48-4.39(m, 4H), 4.37-4.34(m, 1H), 2.66-2.62(m, 1H), 2.40-2.34(m, 1H)

[0693] Example 130: Preparation of 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0694]

[0695] 1H NMR (400MHz, DMSO) δ8.21 (s, 1H), 7.93-7.86 (m, 4H), 7.85-7.83 (d, 1H), 7.79-7.71 (m.1H), 7.69-7.61(d, 1H), 7.47-7.44(dd, 1H), 7.32-7.29(m, 2H), 6.95-6.91(d, 1H ), 5.57 (s, 2H), 4.53-4.44 (m, 3H), 4.36-4.30 (m, 1H), 4.11-4.09 (m, 1H), 3.80-3.74 (q, 1H), 3.63-3.57 (q, 1H), 2.09-2.05 (m, 1H), 1.89-1.84 (m, 2H), 1.82-1.78 (m, 1H)

[0696] Example 132: Preparation of (S)-2-(4-(6-(Benzo[d]thiazol-2-ylmethoxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0697]

[0698] 1 H NMR (400MHz, DMSO) δ8.46 (s, 1H), 8.28-8.25 (t, 1H), 8.19-8.13 (m, 3H), 8.08-8.06 (d, 1H), 7 .98-7.96(d,1H),7.88-7.87(m,1H),7.78-7.75(t,1H),7.67-7.65(d,1H),7.51-7.47(t,1H) ,7.41-7.37(t,1H),6.97-6.95(d,1H),5.93(s,2H),5.22-5.19(m,1H),5.01-4.91(m,2H),4 .58-4.52(m, 1H), 4.34-4.28(m, 1H), 2.79-2.74(m, 1H), 2.42-2.38(m, 2H), 2.17-2.02(m, 1H)

[0699] Example 133: Preparation of (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0700]

[0701] 1H NMR (400MHz, DMSO) 8.49 (s, 1H), 7.99-7.91 (m, 3H), 7.87-7.82 (m, 2H), 7.78- 7.70 (m, 3H), 7.64-7.61 (m, 1H), 7.26-7.24 (d, 1H), 6.93-6.89 (dd, 1H), 5.61 (s, 2H), 5.10-5.08 (m, 1H), 4.76-4.63 (m, 1H), 4.54-4.52 (m, 3H), 4.52-4.50 (m, 1H), 4.43-4.41 (m, 1H), 2.71-2.68 (m, 1H), 2.46-2.43 (m, 1H), 2.32 (s, 3H)

[0702] Example 134: Preparation of (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0703]

[0704] 1 H NMR (400MHz, DMSO) δ8.22 (s, 1H), 7.91 (s, 1H), 7.84-7.78 (m, 3H), 7.63-7.48 (m, 4H), 7.33-7.31 (dd, 1H), 7.17-7.15 (d, 1H), 6.84-6 .82(d,1H),5.51(s,2H),5.03-5.02(m,1H),4.64-4.62(m,1H),4.53-4.35(m,5H),2.68-2.67(m,1H),2.38-2.36(m,1H),2.35(s,3H)

[0705] Example 135: Preparation of (S)-2-(4-(6-(cyclopropylmethoxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0706]

[0707] 1H NMR (400MHz, DMSO) δ8.30 (s, 1H), 8.21-8.16 (m, 2H), 8.14-8.11 (d, 1H), 8.01-7.98 (dd, 1H), 7.89-7.85 (t, 1H), 7.75-7.72 (d 1H), 7.55-7.53(dd, 1H), 6.94-6.91(d, 1H), 5.11-5.08(m, 1H), 4.97-4.87(m, 2H), 4.39-4.34(m, 1H), 4.23-4.18(d, 2H), 4.14- 4.09 (m, 1H), 2.67-2.61 (m, 1H), 2.30-2.24 (m, 1H), 1.34-1.30 (m, 2H), 0.88-0.84 (m, 1H), 0.59-0.56 (m, 2H), 0.39-0.35 (m, 2H)

[0708] Experimental Example 1: cAMP activity test

[0709] The efficacy of the compounds according to the present invention as GLP-1 receptor agonists was determined by measuring cAMP (cyclic adenosine monophosphate) activity using CHO-K1 / GLP-1 receptor expressing cells (Genscript, M00451) expressing human GLP-1 receptor.

[0710] Specifically, CHO-K1 / GLP1 receptor expressing cells in Ham's F12 medium containing 10% FBS, 1% NEAA, 200ug / ml Zeocin and 100ug / ml Hygromycin B were distributed to 96-well plates (SPL, 30096) at a density of 30,000 cells / 100uL / well and cultured in an incubator at 37°C and 5% CO2. The next day, the medium was removed and 50uL of HBSS medium containing 0.1% BSA, 0.5mM IBMX and 5mM HEPES was added to each well. After dissolving a 2× concentration of a test substance (6.4nM to 20uM) in HBSS medium containing 0.1% BSA, 0.5mM IBMX and 5mM HEPES, 50uL of HBSS medium containing the test substance was added to each well and cultured in an incubator at 37°C and 5% CO2. cAMP activity was measured using a cAMP dynamic HTRF kit (Cisbio, 62AM4PEC) according to the manufacturer's instructions. After incubation, the culture medium was discarded and the cells were lysed. cAMP-d2 and anti-cAMP cryptate conjugates were added thereto and reacted for 3 hours. After the reaction was completed, fluorescence was measured using a microplate reader (Molecular Device, Flexstation 3) (excitation wavelength of 313 nm, emission wavelengths of 665 nm and 620 nm). cAMP activity is displayed by fluorescence resonance energy transfer (FRET) that occurs when cAMP-d2 and anti-cAMP-cryptate are very close to each other and calculated according to the 665nm / 620nm fluorescence ratio. Intracellular cAMP competes with cAMP-d2 for anti-cAMP cryptate, and the measured signal of fluorescence resonance energy transfer (FRET) is inversely proportional to intracellular cAMP. The activity of the compound is calculated based on the degree of change in the FRET signal, and the EC of the compound is 50 As shown in Table 1 below.

[0711] [Table 1]

[0712]

[0713]

[0714] Experimental Example 2: hERG inhibition test

[0715] In order to measure the hERG (human rapid delayed rectifier potassium channel gene (ether-a-go-go-related gene)) channel inhibition rate of the compound according to the present invention, the following test was performed using the Predictor hERG fluorescence polarization assay kit (Invitrogen, PV5365).

[0716] Specifically, the test substance was dissolved in DMSO to prepare a 50mM solution. A 4mM solution was prepared by diluting a 50mM solution with DMSO in a U-bottom 96-well plate (SPL, 34096), and then diluted 100 times with test buffer to prepare a 40uM (4×) solution. The positive control E-4031 (3mM) provided in the kit was diluted 25 times with test buffer to make a 120uM solution. 5uL of the diluted test substance solution was distributed into a 384-well assay plate (coming, 3677). 10uL and 5uL of the hERG membrane (2×) and tracer (4×) provided in the kit were added respectively, and reacted at room temperature for 2.5 hours. After the reaction was completed, fluorescence polarization (mP) was measured with a multi-template plate reader (Perkin-Elmer, Envision) (excitation wavelength was 531nm and emission wavelength was 579nm). The inhibitory activity percentage (inhibition %) value of each test substance at 10uM was calculated by the following equation, and the results are shown in Table 2:

[0717] (Inhibition %) = 100 - {(mP-E-4031mP of the compound of the present invention) / (mP-E-4031mP of the solvent control)} × 100

[0718] [Table 2]

[0719]

[0720]

[0721] Experimental Example 3: CYP inhibition test

[0722] CYP inhibition was tested to confirm the effects of the compounds of the invention on liver metabolizing enzymes. For CYP1A2, CYP2C19 and CYP3A4, Corning (459500, 459400, 459100) kits were used, and for CYP2C9 and CYP2D6, Invitrogen (P2861, P2862) kits were used, and the detection methods basically followed the detection methods of each manufacturer.

[0723] The test compound was initially prepared by diluting the compound in DMSO (Sigma, 276855) to a concentration of 50 mM. For the Coming product, the test compound (50 mM) was diluted in acetonitrile to a concentration of 50× (10 uM) of the final concentration, and the NADPH-coenzyme mixture and the enzyme-substrate mixture were mixed at the predetermined concentrations provided by the kit, depending on the type of enzyme. 4 uL of the 50× test compound and 96 uL of the NADPH-coenzyme mixture were mixed in a U-bottom 96-well plate, and then reacted in a 37°C incubator for 10 minutes. Next, 100 uL of the enzyme-substrate mixture was added and reacted in a 37°C incubator for 15 minutes (CYP1A2) or 30 minutes (CYP2C19, CYP3A4), respectively. At the end of the reaction time, 75uL of reaction stop solution (0.5M Tris base ((HOCH2)3CNH2)) was added to terminate the reaction, and the reaction product was transferred to a white plate, and the fluorescence wavelength was read by a microplate reader (Molecular Device, Flexstation 3) (for CYP1A2 and CYP2C19, the excitation wavelength was 410nm and the emission wavelength was 460nm; for CYP3A4, the excitation wavelength was 409nm and the emission wavelength was 530nm).

[0724] For Invitrogen products, the test compound (50mM) was diluted in the test buffer to a concentration of 2.5× (10uM) of the final concentration. Depending on the type of enzyme, the enzyme mixture and the substrate mixture were mixed at the predetermined concentrations provided by the kit. 80uL of 2.5× test compound prepared in a U-bottom 96-well plate was mixed with 100uL of enzyme mixture and reacted for 10 minutes. Then, 20uL of substrate mixture was added thereto and reacted for 1 hour. After the reaction was completed, the reaction product was transferred to a white plate and the fluorescence wavelength was read by a microplate reader (Molecular Device, Flexstation 3) (for CYP2C9, the excitation wavelength was 415nm and the emission wavelength was 460nm; for CYP2D6, the excitation wavelength was 415nm and the emission wavelength was 520nm). The inhibition rate was calculated according to the residual activity value of the test compound-treated group compared with the solvent control group, using the fluorescence value of the solvent control group as the 100% activity value, as shown in the following equation:

[0725] Result value (remaining activity; unit %) = (fluorescence value of test compound / fluorescence value of solvent control) × 100

[0726] The results are shown in the following Tables 3 to 7. Each result value is expressed in % in the following Tables 3 to 7.

[0727] [Table 3]

[0728]

[0729]

[0730] [Table 4]

[0731]

[0732] [Table 5]

[0733]

[0734]

[0735] [Table 6]

[0736]

[0737]

[0738] [Table 7]

[0739]

[0740]

Claims

1. A compound represented by the following formula 1 or a pharmaceutically acceptable salt thereof: [Formula 1] in A is for C 6-10 Aryl, B is any one of the following (1) to (5), L is -(CH2) n -O- or -O-(CH2) n -, where n is 1 or 2, X is CH or N, R1 is hydrogen, C 1-5 Alkyl, C 1-5 Alkoxy, C 1-5 haloalkyl, halogen, cyano or nitro, R2 is hydrogen or halogen, R3 is hydrogen or halogen, R4 is hydrogen, C 1-5 Alkyl, C 1-5 Alkoxy or halogen, R5 is hydrogen or halogen, R6 is -CH2F; furyl; imidazolyl which is unsubstituted or substituted by methyl or ethyl; oxazolyl; pyridyl; thienyl; or tetrahydrofuranyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A is phenyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L is -CH2O- or -OCH2-.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl, methoxy, trifluoromethyl, fluorine, chlorine, bromine, cyano or nitro.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen, fluorine, chlorine or bromine.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, fluorine, chlorine or bromine.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, methyl, methoxy, fluorine, chlorine or bromine.

8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R5 is hydrogen, fluorine, chlorine or bromine.

9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein The compound is represented by the following formula 1-1: [Formula 1-1] in, Y is CH or N; and A, L, X and R1 to R6 are as defined in claim 1.

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein The compound is represented by the following formula 1-2: [Formula 1-2] wherein Y is CH or N; and X and R1 to R6 are as defined in claim 1.

11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein The compound is represented by the following formula 1-3: [Formula 1-3] in Z is CH or N; and A, L, X and R1, R2, R3 and R6 are as defined in claim 1.

12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: The compound is represented by the following formula 1-4: [Formula 1-4] in Z is CH or N; and X and R1, R2, R3 and R6 are as defined in claim 1.

13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: The compound is selected from the group consisting of: 1) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 8) 2-((3'-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 9) 2-((3'-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 10) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 11) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 12) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 13) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 14) 2-((3'-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 15) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 16) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 17) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 18) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 19) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 23) 1-(furan-2-ylmethyl)-2-((5-(3-(3-methoxybenzyloxy)phenyl)pyridin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 24) 2-((3'-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 27) 2-((3'-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 28) 2-((3'-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 29) 2-((3'-(4-cyano-2-fluorobenzyloxy)-2-methylbiphenyl-4-yl)methyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 30) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 32) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 33) 2-((3'-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 34) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 35) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 41) (R)-2-((3'-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 42) (R)-2-((3'-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 43) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 44) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 45) (R)-2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 46) (R)-2-((3'-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 47) (R)-2-((3'-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 49) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(thien-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 50) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 51) (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 52) (R)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 55) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 56) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 57) 2-((3'-(4-cyano-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 58) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-fluoroethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 59) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 60)(S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 61) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 62) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 63) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 64) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 65) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 66) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 67) (S)-2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 68) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 69) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 70) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 71) 2-(4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 72) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 75) 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 76) 2-(2-fluoro-4-(6-(4-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 77) 2-(2-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 80) 2-(2-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 81) 2-(2-fluoro-4-(6-(3-methoxybenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 83) 2-(4-(6-(Benzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 85) 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 87) 2-(4-(6-(4-cyanobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 88) 2-(2-fluoro-4-(6-(4-nitrobenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 89) 2-(4-(6-(4-bromo-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 90) 2-(3-fluoro-4-(6-(3-methylbenzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 91) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)-5-fluoropyridin-2-yl)-2-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 92) 2-((3'-(4-chloro-2-fluorobenzyloxy)-2,4'-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 93) 2-((3'-(4-cyano-2-fluorobenzyloxy)-2,4'-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 94) 2-(4-(6-(4-chlorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 95) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3,4'-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 96) 2-((3'-(4-cyano-2-fluorobenzyloxy)-3,4'-difluorobiphenyl-4-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 97) 2-(3-fluoro-4-(6-(4-(trifluoromethyl)benzyloxy)pyridin-2-yl)benzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 98) 2-(4-(6-(3,4-difluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 99) 2-(4-(6-(4-chloro-3-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 100) 2-(4-(6-(3-chloro-5-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 101) 2-(4-(6-(2-chloro-6-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 102) 2-((5-(3-(4-chloro-2-fluorobenzyloxy)-4-fluorophenyl)pyridin-2-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 105) 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 106) 2-((4-(3-(4-chloro-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 107) 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 108) (S)-2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 109) (S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 112) 2-((4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-6-oxopyrimidin-1(6H)-yl)methyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 116) (S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 120)(S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 130) 2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid.

14. A compound or a pharmaceutically acceptable salt thereof, wherein: The compound is selected from the group consisting of: 2) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)benzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 3) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 4) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 5) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 6) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-3-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 7) 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-nitrobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 21) 2-((3'-(4-cyano-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 22) 2-((3'-(4-chloro-2-fluorobenzyloxy)biphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 31) 2-(4-(6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)-2-fluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 36) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 37) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 39) 2-((3'-(4-chloro-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 40) 2-((3'-(4-cyano-2-fluorobenzyloxy)-2-fluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 48) 2-((3'-(4-chloro-2-fluorobenzyloxy)-3,5-difluorobiphenyl-4-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 53) 2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2-methylbenzyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 82)(S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 84)(S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,6-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 86) (S)-2-(4-(6-(4-chloro-2-fluorobenzyloxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 104) 2-((4-(3-(4-cyano-2-fluorobenzyloxy)phenyl)-2-oxopyridin-1(2H)-yl)methyl)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 110)(S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-2'-oxo-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 111)(S)-2-((4-(6-(4-cyano-2-fluorobenzyloxy)pyridin-2-yl)-2-oxopyridin-1(2H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 113) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,3-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 115) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-difluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 118) (S)-2-(4-(6-((4-cyanobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 119) (S)-2-(4-(6-((2,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 121)(S)-2-(3-fluoro-4-(6-((4-(trifluoromethyl)benzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 122) (S)-2-(3-fluoro-4-(6-((4-methoxybenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 123) (S)-2-(4-(6-((4-chlorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 124) (S)-2-(3-fluoro-4-(6-((4-nitrobenzyl)oxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 125)(S)-2-(4-(6-((3,4-difluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 126) (S)-2-(4-(6-((2-chloro-6-fluorobenzyl)oxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 127) 2-((6-((4-chloro-2-fluorobenzyl)oxy)-2'-oxo-[2,4'-bipyridyl]-1'(2'H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 128) (S)-2-(3-fluoro-4-(6-(pyridin-4-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 129) (S)-2-(3-fluoro-4-(6-(pyridin-3-ylmethoxy)pyridin-2-yl)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 131)(S)-2-((4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 132) (S)-2-(4-(6-(Benzo[d]thiazol-2-ylmethoxy)pyridin-2-yl)-3-fluorobenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, 133) (S)-2-(4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, and 134)(S)-2-(4-(6-((4-chloro-2-fluorobenzyl)oxy)pyridin-2-yl)-2-methylbenzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid.

15. A pharmaceutical composition for preventing or treating a disease associated with GLP-1 activity, comprising the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition according to claim 15, wherein The disease associated with GLP-1 activity is diabetes, hyperglycemia, diabetic neuropathy, diabetic nephropathy, obesity, dyslipidemia, cardiovascular disease, or non-alcoholic fatty liver disease.